Glaxo.doc.doc
Upcoming SlideShare
Loading in...5
×
 

Glaxo.doc.doc

on

  • 2,185 views

 

Statistics

Views

Total Views
2,185
Views on SlideShare
2,185
Embed Views
0

Actions

Likes
0
Downloads
14
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Glaxo.doc.doc Glaxo.doc.doc Document Transcript

  • Proposal: Relationships between the Prescription Rate of 5- α−reductase Inhibitors and the Utilization Rate of Surgical Therapies in the Treatment of Benign Prostatic Hyperplasia By the Duke Department of Urology1 and the Duke Center for Clinical and Genetic Economics2 Authors David M. Albala, M.D.1 Lesley H. Curtis, Ph.D.2 Jeffrey Sung Kevin A. Schulman, M.D., M.B.A.2
  • 1.0 Introduction Transurethral resection of the prostate (TURP) was once the standard of therapy for benign prostatic hyperplasia (BPH). The number of TURPs within the Medicare program peaked in 1987 when 258,000 were performed (Holtgrewe, 1998). Since then, a steady decline in the number of TURPs has accompanied improvements in the effectiveness of medical therapy and the development of less invasive surgeries (Wasson, 2000). In 1992, one of the biggest advances in the medical therapy of BPH was made with the introduction of the first 5-α−reductase inhibitor (finasteride). Prior to finasteride, medical therapy had consisted primarily of symptomatic treatment with α−blockers in an attempt to delay or avoid the necessity of surgical intervention. However, long-term studies have since shown that finasteride is capable of altering the natural history of benign prostatic hyperplasia and reducing the rates of acute urinary retention and surgery (McConnell, 1998). While TURP rates have fallen, the advancement of several minimally invasive procedures has led to the increasing use of these techniques for the treatment of BPH. Today, the most common ones include transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), interstitial laser therapy (ILT), visual laser ablation of the prostate (VLAP), transurethral vaporization of the prostate (TUEP) and high intensity focused ultrasound (HIFU). Early results for most of these therapies have shown low and acceptable re-treatment rates and shorter hospital stays (Tunuguntla, 2002). Additionally, cost-effectiveness models have suggested little difference in value between medical therapy and minimally invasive surgery for patients with moderate to severe BPH symptoms (Manyak, 2002). The question remains to what extent the increasing use of finasteride has resulted in a decrease in the utilization rate of total surgical procedures. We are pleased to provide a proposal to study this question based on the request for proposal forwarded to Dr. David Albala by GlaxoSmithKline representatives. 2.0 Research Objective and Specific Aims The overall goal of the proposed study is to examine the relationships between the prescription rate of finasteride and the utilization rates of surgical interventions for BPH. Aim 1.0. To assess the temporal relationship between the use of finasteride, TURPs, and minimally invasive surgical therapies for BPH over an eight year period from January 1, 1993 to December 31, 2000. Aim 2.0. To identify the market characteristics and socio-demographic factors associated with geographic variations in the utilization of finasteride, TURPs, and minimally invasive surgical therapies. 3.0 Research Design and Methods 3.1 Overview of Data Sources
  • 3.1.1 Data sources for Aim 1.0 A nationwide, 5% random sample of Medicare beneficiaries will provide monthly estimates of the use of TURP and minimally invasive surgical therapies in the treatment of BPH from 1993 through 2000. The file, maintained by the Health Care Financing Administration, is commonly used for research purposes. The enrollment file contains demographic information on each Medicare beneficiary, and the claims files contain expenditure and use at the individual beneficiary level for all Medicare-covered services. We will aggregate the claims on a monthly basis in order to generate monthly estimates of national estimates of the use of TURP and minimally invasive therapies. Identification of TURP will be based on the presence of Current Procedural Terminology (CPT) codes 52601, 52612, 52614, 52620 or 52630 in their hospital claims. Identification of minimally invasive surgical therapies, which will include TUNA, TUMT, ILT, VLAP, TUEP and HIFU, will be based on the presence of CPT codes 53850, 53851, 53852, 53853, 52647 or 52648 in their outpatient claims. We will obtain monthly prescription data from January 1, 1993 through December 31, 2000 from Verispan’s Source ™ Prescription Audit (SPA). SPA provides a comprehensive overview of the national performance of all prescription drugs dispensed by retail pharmacies. Each month over 140 million prescriptions are collected, projected and summed to the national level from more than 35,000 U.S. retail pharmacies, including chains, independents, mass merchandisers and food stores. Data are collected electronically at the point of pharmacy and cover nearly 70% of all dispensed prescriptions. Identification of finasteride used for benign prostatic hyperplasia will be based on the prescription of the 5 mg dosage, or NDC codes 54569-8597, 00006-0072 and 54868-2719. We will obtain corresponding prescription data for tamsulosin, the leading α−blocker, to control for its effects on surgical utilization rates. Identification of tamsulosin used for benign prostatic hyperplasia will be based on the prescription of the 0.4 mg dosage, or NDC codes 54569-4768, 00339-5560, 00597-0058, 51248-0058, 54868-4356, 12838-0058. 3.1.2 Data sources for Aim 2.0 We will use selected Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SIDs) in order to estimate the use of TURP at the zip code (or FIPS county code level) in the year 2000. The SIDs contain more than 100 clinical and nonclinical variables included in a hospital discharge abstract, such as principal and secondary diagnoses; principal and secondary procedures; admission and discharge status; patient demographics (e.g., gender, age, and, for some States, race); and resource utilization (total charges, length of stay). Identification of TURP will be based on the presence of CPT codes 52601, 52612, 52614, 52620 or 52630 in their hospital claims. To estimate the use of minimally invasive surgical techniques at the zip code (or FIPS county code level) in the year 2000, we will acquire selected HCUP State Ambulatory Surgical Databases (SASD). The SASD contain the ambulatory surgery encounter abstracts in participating States, translated into a uniform format to facilitate multi-state comparisons and analyses. For these encounters, the SASD captures a core set of clinical and non-clinical information on all patients, regardless of payer, including persons
  • covered by Medicare, Medicaid, private insurance, and the uninsured. Identification of minimally invasive surgical therapies, which will include TUNA, TUMT, ILT, VLAP, TUEP and HIFU, will be based on the presence of CPT codes 53850, 53851, 53852, 53853, 52647 or 52648 in their outpatient claims. For both the SID and the SASD, we will acquire data from Florida, New York, New Jersey, North Carolina and Pennsylvania. These states are 5 of the top 10 states in terms of population over age 65 and are home to approximately 26% of the nation’s elderly population. (Census 2000). In addition, the SID and SASD for these states include hospital and county identifiers that permit linkage to the American Hospital Association Annual Survey File and the Area Resource File. We will obtain data regarding finasteride dispensings at the zip code level from Verispan’s Prescription Database for the period of January 1, 2000 to December 31, 2000. Each month over 140 million prescriptions are collected from more than 35,000 U.S. retail pharmacies, including chains, independents, mass merchandisers and food stores. Data are collected electronically at the point of pharmacy and cover nearly 70% of all dispensed prescriptions. Identification of finasteride used for benign prostatic hyperplasia will be based on the prescription of the 5 mg dosage, or NDC codes 54569-8597, 00006-0072 and 54868-2719. We will obtain corresponding prescription data for tamsulosin, the leading a-blocker, to control for its effects on surgical utilization rates. Identification of tamsulosin used for benign prostatic hyperplasia will be based on the prescription of the 0.4 mg dosage, or NDC codes 54569-4768, 00339-5560, 00597-0058, 51248-0058, 54868-4356, 12838-0058. To the data from the SID, SASD, and Verispan, we will merge data from the 2000 Area Resource File (ARF). The ARF is a database containing information on health facilities, health professions, measures of resource scarcity, economic activity, and socio- demographic characteristics for each county in the U.S. 3.2 Study Time Period The analysis for Aim 1.0 will focus on an eight year period from January 1, 1993 through December 31, 2000. The time period is sufficiently long to capture necessary variations in medical therapy prescription rates and surgical procedure rates since the introduction of finasteride and those minimally invasive surgical therapies listed above. The analysis for Aim 2.0 will focus on a one year period from January 1, 2000 to December 31, 2000. This time period is sufficient for a cross-sectional study of utilization patterns of medical therapy and surgical procedures. 4.0 Research Design and Methods 4.1 General Strategy To test the hypothesis that increases in the use of finasteride have been accompanied by decreases in the use of surgical procedures, we will model total monthly surgical rates,
  • including both TURPs and minimally invasive surgeries, as a function of time, monthly claims of finasteride, monthly claims of tamsulosin, and real Medicare reimbursement levels for TURP. Additionally, to isolate the effects of all other therapies on TURPs, we will model monthly TURPs as a function of time, monthly claims of finasteride, monthly claims of tamsulosin, monthly rates for minimally invasive surgical therapies, and real Medicare reimbursement levels for TURP. To explore geographic variations in the use of finasteride, we will proceed in a two-stage process in order to ensure value for GlaxoSmithKline. In the first stage, we will calculate standard measures of variation in finasteride usage as described below in “Descriptive Analyses”. If the geographic variations meet the prespecified levels, we will continue to the second stage. In this phase, we will model annual finasteride claims at the zip code level as a function of annual claims of tamsulosin, annual TURP rates, annual rates for minimally invasive surgical therapies, and variables regarding health facilities, health professions, measures of resource scarcity, economic activity, and socio-demographic characteristics. 4.2 Descriptive Analyses In our temporal study of the period from January 1, 1993 to December 31, 2000, for each year, we will use graphical techniques to describe trends in the use of finasteride, tamsulosin, minimally invasive therapy and TURP. In our cross-sectional study of populations in New York, Florida, New Jersey, North Carolina and Pennsylvania, we will calculate standard measures of variation including the weighted coefficient of variation (COV), and the systematic component of variation (SCV). The weighted COV is the ratio of the standard deviation of the prevalence rates to the mean rate among the state, weighted by the population in each state. The SCV estimates the variance across states that cannot be explained by the variation within the state. McPherson and colleagues provide a detailed explanation of the SCV. (McPherson, 1981) In order to proceed to the second stage of analysis, we will require that the calculated values for the COV and the SCV meet or exceed the 95th percentile levels established by Diehr and colleagues generated using an iterative resampling process for various sampling schemes and prevalence rates. (Diehr, 1990) Assuming that finasteride is used by 2% of men aged 65 and older (estimated from the 1999 Medical Expenditure Panel Survey), a COV in excess of 0.05 and an SCV in excess of 8.5 would suggest that significant variation exists. 4.3 Models for Utilization Aim 1.0 requires that we model total monthly surgical utilization rates as a function of time, Medicare TURP reimbursement rates, and prescription claims for finasteride and tamsulosin. We will also model TURP rates as a function of time, Medicare TURP reimbursement rates, minimally invasive surgery rates, and prescription claims for finasteride and tamsulosin,
  • The most straightforward approach for this aim is to use linear regression to estimate the coefficients. The general form of the equation to be estimated is as follows: Yi = β 0 +∑ β j X ji +U i where Yi represents the surgical utilization rate, βo is an intercept term, the βjs are the regression coefficients relating the different variables to the surgical therapy use, and Ui is the error term. Because Aim 1.0 relies on time series data, we expect to encounter autocorrelation. That is, we expect that time series values at time t will depend on the values at another time, t-1. To account for this likely dependence, we will estimate a linear regression that is corrected for first-order serial correlation using the Prais-Winstein transformed regression estimator. (Prais and Winstein, 1954) The Prais-Winstein estimator is a generalized least squares estimator that uses an iterative process to incorporate the correlation of the residuals into coefficients. Aim 2.0 requires that we model annual finasteride claims at the county level as a function of county-level surgical utilization rates, supply of health facilities and health professionals, overall economic activity, and socio-demographic characteristics. The linear regression model is also best suited for this purpose, where Yi represents finasteride claims, βo is an intercept term, the βjs are the regression coefficients relating the different variables to the finasteride use, and Ui is the error term. One problem with applying multiple regression to the geographic data in Aim 2.0 is that geographic areas may vary considerably in population size and in the number of events of interest. (Pocock, 1981) Areas with large populations provide the most reliable estimates and should therefore be weighted more heavily. In this analysis, we will use a weighting procedure developed by Pocock et al. that uses the relative contribution of sampling error to the unexplained variation between counties to determine weights. (Pocock, 1981) 5.0 Deliverables Based on the results of Aim 1, one manuscript will be prepared for submission to a professional journal. Assuming sufficient variation in finasteride use is found in stage one of Aim 2, a second manuscript will be prepared for submission to a professional journal. In addition, A report of the overall analyses with discussion will be submitted to the sponsor. 6.0 Project Budget The budget for Aim 1, inclusive of data acquisition costs, is $ 134,843. The budget for Aim 2, inclusive of data acquisition costs, is $122,180. Travel time and travel expenses are not included.
  • Relationships between the Prescription Rate of 5-α− reductase Inhibitors and the Utilization Rate of Surgical Therapies in the Treatment of Benign Prostatic Hyperplasia Tasks AIM 1 I. Start Up/Literature Review/ IRB Preparation and Submission $5,985 II. Data Acquisition $43,600 III. Data Processing $4,485 IV. Data Analysis $25,225 V. Manuscript $25,805 Subtotal AIM 1 $105,100 Indirect Costs @ 28.3% $29,743 Total Costs AIM 1 $134,843
  • AIM 2/STAGE 1 I. Preliminary Assessment of Geographic Variations $9,555 Subtotal AIM 2/ STAGE 1 $9,555 Indirect Costs @ 28.3% $2,704 Total Costs AIM 2/ STAGE 1 $12,259 AIM 2/ STAGE 2 I. Literature Review $4,485 II. Data Acquisition $22,410 III. Data Processing $13,535 IV. Data Analysis $28,995 V. Manuscript $25,805 Subtotal AIM 2/STAGE 2 $95,230 Indirect Costs @ 28.3% $26,950 Total Costs AIM 2/STAGE 2 $122,180 7.0 Project Timeline Estimated Project Start Date: August 1, 2003 Timeline: Planning/Startup 1.5 Months August 1, 2003 – September 15, 2003 Data Preparation 3.5 Months September 15, 2003 – January 15, 2004 Statistical Analysis 4.5 Months January 15, 2004 – June 1, 2004 Manuscripts 2.5 Months June 1, 2004 – July 31, 2004 Total Timeline: 12 Months August 1, 2003 – July 31, 2004 8.0 Collaborators This proposal brings together a multi-disciplinary team with considerable expertise in urology, economics, health services research and policy analysis. Collaborators include: David M. Albala, MD Professor of Urology, Duke University Medical Center Lesley H. Curtis, PhD, MS Research Associate and Director, CERTs Data Center, Duke Clinical Research Institute Jeffrey C. Sung
  • Candidate for MD/MBA, Duke School of Medicine and Fuqua School of Business Kevin A Schulman, MD, MBA Professor of Medicine, Duke University Medical Center Professor of Business Administration, Fuqua School of Business, Duke University Director, Center for Clinical and Genetic Economics, Duke Clinical Research Institute 9.0 References Diehr P, Cain K, Connell F, Volinn E. What is too much variation? The null hypothesis in small-area analysis. Health Services Research 1990;24:741-771. Holtgrewe, HL. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 51 (Suppl 4A): 1-7, 1998. Manyak, MJ, Ackerman, SJ, Blute, ML, et al. Cost effectiveness of treatment for benign prostatic hyperplasia: An economic model for comparison of medical, minimally invasive, and surgical therapy. Journal of Endourology 16:1, February 2002. McConnell, JD, Bruskewitz, R, Walsh, P, et al, and the Finasteride Long-Term Efficacy and Safety Study Group: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New England Journal of Medicine 338: 557-563, 1998. McPherson K, Strong PM, Epstein A, Jones L. Regional variations in the use of common surgical procedures: within and between England and Wales, Canada and the United States of Americal. Soc Sci Med [A]. 1981;15(3 pt 1):273-288. Pocock S, Cook D, Beresford S. Regression of area mortality rates on explanatory variables: What weighting is appropriate? Applied Statistics 1981;30:286-95. Prais SJ, Winstein CB. Trend estimators and serial correlation. (1954) Cowle Commission Discussion Paper No. 383. Chicago, IL. Tunuguntla, HS, Evans, CP. Minimally invasive therapies for benign prostatic hyperplasia. World Journal of Urology 20: 197-206, 2002. Wasson, JH, Bubolz, TA, Lu-Yao, GL, Walker-Corkery, E, Hammond, CS and Barry, MJ for the PORT for Prostatic Diseases. Transurethral resection of the prostate among medicare beneficiaries: 1984 to 1997. The Journal of Urology 164: 1212-1215, October 2000.
  • Appendix A: Duke Clinical Research Institute Description and Capabilities The Duke Clinical Research Institute (DCRI) is a full-service contract research organization committed to an academic mission, yet focused on customer service. True to our academic foundation, our mission is “To develop and share knowledge that improves the care of patients around the world through innovative clinical research.” Specifically, we believe that our organization’s fundamental motivation must be to improve care for patients by promoting an evidence-based approach to health care via clinical trials and outcomes research. Fidelity to this mission has allowed our organization to gain considerable research credibility, rivaling the best commercial research organizations in the world. The DCRI designs and conducts large and small multinational clinical studies, and we employ over 750 people to ensure the flexibility to meet the needs of all current projects and this proposal. We maintain the oldest and largest cardiovascular database in the world and have conducted the largest thrombolytic trial in history (41,021 patients in 15 countries). We have conducted over 75 clinical trials, involving 4200 investigators at over 3120 sites in more than 50 countries. Overall, we have enrolled more than 180,000 patients in clinical trials. We have expanded our capabilities steadily over the past decade and have an extensive faculty and staff experienced in the conduct of clinical trials, capable of running multiple large and small studies simultaneously. We are organized into functional groups— including a world-renowned group of outcomes and health services researchers— designed to maximize performance in our core research areas of clinical investigative trials, outcomes studies, registries, and data base analyses. The DCRI’s Center for Clinical and Genetic Economics (CCGE) and its Outcomes Research and Assessment Group has 26 full-time faculty and over 80 full-time support staff devoted solely to outcomes research, including clinicians, health economists, statisticians, and health services researchers. This group leads the nation in the collection of economic and quality of life data for clinical research and has so far conducted over 20 large-scale economic and quality of life studies alongside randomized controlled trials. With this impressive array of resources, the DCRI is uniquely poised as an international leader in applying quantitative measurements and methods to clinical research and the practice of medicine. The DCRI fills this role efficiently and cost-effectively, while remaining a customer-focused and performance-driven organization.
  • Appendix B: Curriculum Vitae of David M. Albala CURRICULUM VITAE NAME: David Mois Albala, M.D., F.A.C.S. HOME ADDRESS: OFFICE ADDRESS: 904 Bayberry Drive Duke University Medical Center Chapel Hill, NC 27517 Department of Surgery (919) 942-9415 Division of Urology E-mail: dmalbala@aol.com DUMC Box 3457 Rm. 1112 Green Zone Davison Bldg. Trent Drive Durham, NC 27710 (919) 684-5416 (Direct Line) (919) 681-7423 (Fax) E-mail: albal002@mc.duke.edu WIFE: Francine A. Salerno 10/23/99 DATE AND PLACE OF BIRTH: December 29, 1955; Chicago, IL SOCIAL SECURITY NUMBER: 035-40-5462 EDUCATION: Michigan State University M.D. College of Human Medicine June 1983 East Lansing, Michigan 48824 Brown University Program in Medicine Student Providence, Rhode Island 02912 1979 - 1981 Lafayette College A.B. Honors in Geology Easton, Pennsylvania 18042 June 1978 Harvard University Visiting Scholar Cambridge, Massachusetts 02138 1977 Kings College English Speaking Union Taunton, Somerset, England Scholarship, 1974 POST DOCTORAL TRAINING:
  • 1990 - 1991 Fellow in Endourology and Stone Disease, Barnes Hospital, Washington University School of Medicine, St. Louis, Missouri 63108 (under the direction of Ralph V. Clayman, M.D.) 1989 - 1990 Chief Resident, Urology, Dartmouth-Hitchcock Medical Center Hanover, New Hampshire 03756 1989 Senior Resident, Pediatric Urology, Massachusetts (Jan-March) General Hospital Boston, Massachusetts 02114 (under the direction of Patricia K. Donahoe, MD) 1988 - 1989 Senior Resident, Urology, Dartmouth-Hitchcock Medical Center Hanover, New Hampshire 03756 1987 - 1988 Research Resident, Urology, Dartmouth-Hitchcock Medical Center Hanover, New Hampshire 03756 (area of concentration: drug-induced nephrolithiasis) 1986 - 1987 Junior Resident, Urology, Dartmouth-Hitchcock Medical Center Hanover, New Hampshire 03756 1984 - 1985 Junior Resident, General Surgery, Dartmouth-Hitchcock Medical Center Hanover, New Hampshire 03756 1983 -1984 Intern, General Surgery, Dartmouth-Hitchcock Medical Center Hanover, New Hampshire 03756 ACADEMIC APPOINTMENT: 2001-Present Professor, Divison of Urology, Duke University Medical Center, Durham, North Carolina 27710 2001-Present Staff Urologist, Veterans Administration Hospital, Durham, North Carolina 27710 1999-2001 Professor, Department of Urology and Radiology, Loyola University, Strich School of Medicine, Maywood, Illinois 60153 1991-2001 Staff Urologist, Veterans Administration Hospital Hines, Illinois 60141
  • 1994.1999 Associate Professor, Department of Urology, Loyola University, Stritch School of Medicine, Maywood, Illinois 60153 1995-1996 Associate Professor, Department of Urology, George Washington Medical Center, Washington, DC 20008 1992.1994 Assistant Professor, Department of Urology, Loyola University Stritch School of Medicine, Maywood, Illinois 60153 1991-1992 Instructor, Department of Urology, Loyola University Stritch School of Medicine, Maywood, Illinois 60153 1990-1991 Clinical Fellow (Urology), Washington University School of Medicine, St. Louis, Missouri 63110 1989-1990 Clinical Instructor (Urology), Dartmouth Medical School, Hanover, New Hampshire 03756 FELLOWSHIP DIRECTOR: 2001-Present Co-Director of the Duke University Endourology Fellowship Program, approved by the Endourological Society 1996-2001 Director of The Loyola University Endourology Fellowship Program, approved by the Endourological Society LICENSURE/CERTIFICATION: State of North Carolina, 2001-current (2002-01164) State of New Hampshire, 1984 - 2002 (#7609) State of Illinois, 1991-2002 (036-083171) State of New York, 1993 - 1995 (193729) State of Vermont, 1984 - 1998 (#42-0007234) State of Missouri, 1990-1991 (T-17094) State of Massachusetts, 1989 - 1990 (#967768) Basic Cardiac Life Support - 1984 - current Advanced Trauma Life Support - 1984 - current Advanced Cardiac Life Support Instructor - 1986 - current Advanced Life Support - 1985 - current Federal Licensing Examination (FLEX) - 1984 Extracorporeal Shock Wave Lithotripsy (Dornier)- Mass. General Hosp. 1989 Extracorporeal Shock Wave Lithotripsy (Lithostar) - Barnes Hospital - 1990 Urological Laser Certification - Pulse-Dye, Nd-Yag, Indigo, Holmium, CO2-1991 American Board of Urology (Parts I and II) - certified- 1994; re-certified 2001
  • PROFESSIONAL MEMBERSHIPS/COMMITTEES: Admissions Committee—Duke University Medical School—2002-present American Medical Foundation - 2000 -present American Urological Association - 1986-present American College of Surgeons (Fellow) - 1988 -present American Medical Association - 1988-present American Association for the Advancement of Science - 1989-present American Public Health Association - 1985-present Endourological Society - 1990-present Society for Minimally Invasive Therapy - 1991-present American Association of Clinical Urologists - 1992-present Society of University Urologists - 1992-present Societe Internationale d'Urologie - 1993-present Society for Urology and Engineering - 1992 - present Medical Advisory Committee - American Telemedicine - 1993-present Admission Committee - Loyola Stritch School of Medicine 1994-2001 Medical Record Committee - Loyola University Med. Ctr. - 1993-2001 Surgical Pathology Committee Loyola University Med. Ctr. - 1992-2001 Health Policy Committee, American Urological Association - 1995-1998, 2000-2001 Chicago Urological Society - 1991-2001 Executive Committee - Chicago Urological Society - 1996-2001 Illinois State Urological Society - 1991 -2001 Loyola University Physician Foundation (LUPF) Board Member - 1997-2000 Medical Advisory Committee - Day Surgi Center - 1993-1996 Blood Usage Committee - Loyola University Med. Ctr. - 1992-1998 Grafton County Medical Society - 1986-1990 New Hampshire Urological Society - 1986-1990 Appalachian Mountain Club - Search and Rescue Committee - 1983-1990 Health Advisory Committee - Vermont March of Dimes - 1989-1990 EMPLOYMENT: Division of Urology Professor of Urology Duke University Medical Center 2001-Present Room 1112, Green Zone, DUMC Box 3457 Durham, NC 27710 Director of minimally invasive urologic surgery at a large academic teaching hospital. Involved with endoscopic and laparoscopic surgery, patient care, and resident/medical student education. Engaged in all aspects of laparoscopic and endourological research.
  • Department of Urology Instructor in Urology Loyola University Medical Center 1991-1992 Stritch School of Medicine Assistant Professor of Urology 2160 South First Avenue 1992-1994 Maywood, Illinois 60153 Associate Professor of Urology 1994-1999 Professor of Urology and Radiology 1999-2001 Responsible for the Endourology service at an academic teaching hospital. Involved with endoscopic and laparoscopic surgery, patient care, and resident/medical student education. Currently engaged in laparoscopic and ureteral healing research, as well as uses of fibrin glue in urology. White House Fellowship Office White House Fellow 712 Jackson Place, NW 1995 - 1996 Washington, DC 20503 Served as a special assistant to the Secretary of Transportation, Federico Pena. Responsible for writing speeches, drafting and reviewing proposed legislation answering Congressional inquiries, chairing meeting and conducting briefings. Participated with the Secretary and administration heads on matters pertaining to project plans and policies. Worked on health related issues in the Department of Transportation, both classified and unclassified. Department of Urologic Surgery Endourology Fellow Washington University School of Medicine 1990 - 1991 4960 Children's Place St. Louis, Missouri 63110 Served as the Extracorporeal Shockwave Lithotripsy (ESWL)/Endourology fellow. Responsibilities included patient care, surgery, medical student/resident teaching and research in laparoscopic surgical techniques. Department of Community Health Sciences Special Assistant to the Aga Khan University and Medical College Chairman P.O. Box 3500 Karachio-5, Pakistan 1985 - 1986 Assisted the departmental chairman in managing a complex agenda in a highly dynamic environment - facilitated administrative, academic, and external activities and relationships including developing proposals for external support. Participated in teaching, fieldwork, and direct patient care. Involved in developing primary health care programs for the squatter settlements in urban Karachi.
  • Mount Ascutney Hospital, Windsor, Vermont Emergency Room Northeast Rehab. Hospital, Salem New Hampshire Physician Brattleboro Hospital, Brattleboro, Vermont 1985 - 1991 Rockingham Hospital, Bellows Falls, Vermont Served as a physician in the emergency room. Responsibilities included direct patient care and providing emergency services to the hospital in-patients. Served as a coordinator of the emergency room physician at Mount Ascutney Hospital for four years and served as coordinator of physicians at Northeast Rehabilitation Hospital for five years. Rhode Island Hospital Laboratory Assistant Department of Pathology 1980 Providence, Rhode Island 02945 Assisted in various aspects of surgical and anatomical pathology. Duties included sectioning tissues for various microscopic examinations, photography, and autopsies. Rhode Island Department of Health Researcher Division of Epidemiology, Room 105 1979 (summer) Health Building Providence, Rhode Island 02908 Involved in a rubella research program involving college-aged women. Responsibilities included assessing the impact of a new Rhode Island state law, setting up immunization programs, and handling problems that developed. Brandt Associates, Inc. Laboratory Technician P.O. Box 81 1978 - 1979 Martins Creek, Pennsylvania 18063 Involved in various aspects of water and wastewater testing from the chemical and biological standpoints. Duties included designing a quality control system for the lab, data interpretation, computer work, and routine analyses. Lafayette College Laboratory Instructor Department of Geology 1976 - 1978 Easton, Pennsylvania 18042 Served as a laboratory instructor in an upper level geology course (mineralogy). Responsible for setting up demonstrations, giving lectures, and writing exams.
  • Appalachian Mountain Club Hutmaster/Hutboy Pinkham Notch Camp 1973 - 1976 Summers Gorham, New Hampshire 03581 Involved in operating a mountain hostel in the White Mountains. Duties included packing food supplies, cooking for up to ninety guests, developing mountain education programs and mountain rescue programs. The AMC is the oldest mountaineering/conservation organization in the country. I also worked at their main office in Boston, Massachusetts. AWARDS/DISTINCTIONS: Adolph A. Kutzman Visiting Professor (Cedars-Sinai Medical Center), Los Angeles, CA, November, 2002 Guest Professor, Chi Mei Medical Center, Tainan, Taiwan, May, 2002. Visiting Professor, University of Arkansas Medical Center, April , 2002. Visiting Professor, Medical University of South Carolina (Kenneth M. Lynch Memorial Visiting Professorship), Charleston, South Carolina, November, 2001. Visiting Professor, Singapore General Hospital, Singapore, September, 2001. Visiting Professor, Medical College of Wisconsin, June, 2001. Visiting Professor, Italian Urological Association, Sardenia, Italy, May, 2001. Visiting Professor, Pakistan Urological Association, Karachi, Pakistan, February, 2001. Selected as one of the “Top Doctors in the Chicago Area” as chosen by their peers. Chicago Magazine, January, 2001. Selected as one of the “Best Doctors in America” by peers. Castle Connolly Medical Ltd., Chicago, Illinois, January 2001. Visiting Professor, Icelandic Urological Association, Reykjavik, Iceland, October 2000. 2000 Pfizer/American Urological Association, Visiting Professorship in Urology, June, 2000. Selected as an Outstanding Physician in the Chicago Metropolitan Area: How to Find The Doctors: Chicago Metropolitan Area, Castle Connolly Medical Ltd, Chicago, IL, March, 2000. Visiting Professor, San Diego Naval Hospital, San Diego, California, July, 1999.
  • The Irving J. Shapiro Award - Dedicated to a physician who has performed outstanding service in the urogram conference of the Chicago Urological Society. April, 1999. Visiting Professor, University of Miami, Miami, Florida, March, 1999. Selected as one of the “Top Doctors in the Chicago Area” as chosen by their peers. Chicago Magazine, January, 1997. The Irving J. Shapiro Award - Dedicated to a physician who has performed outstanding service in the urogram conference of the Chicago Urological Society. April, 1997. Judge - The 29th Annual Washington Urological Society’s Resident Scholars Conference, Washington, D.C., February, 1996. White House Fellowship - Selected to spend a year in Washington, D.C. as a special assistant to Federico Pena. June, 1995. Alf H. Gunderson, M.D. Memorial Lecturer - Selected to deliver this memorial lecture at the Gunderson Clinic, LaCrosse, Wisconsin, September, 1995. The Irving J. Shapiro Award - Dedicated to a physician who has performed outstanding service in the urogram conference of the Chicago Urological Society. April, 1995. Visiting Professor, University, University of Florida, Gainesville Fl., March, 1995. Visiting Professor, Tulane University, New Orleans, LA, November, 1994. Visiting Professor, University of California, San Diego, CA, October, 1992. American College of Surgeons Cine-Clinic Award - Laparoscopic Adrenalectomy, October, 1994. Video Urology Award - Laparoscopic Adrenalectomy, August, 1994 Endourological Society Resident/Fellow Award - 2nd place: "Extracorporeal Shock Wave Lithotripsy (ESWL) for Ureteral Calculi: To Stint or Not to Stint." June, 1991. New Hampshire Chapter of the American College of Surgeons Best Trauma paper: "Urological Injury and Assessment in Patients with Pelvic Fractures." January, 1989. New Hampshire Chapter of the American College of Surgeons Best Trauma paper: "Bladder Rupture: A Review of 42 Cases." March, 1988. Awarded the Yoshioka Japan Hospital Association Fellowship (through the International Hospital Federation) to study primary health care programs in selected third world cities. US $4,000 March, 1986.
  • Medical Expedition to eastern Nepal with the Johns Hopkins University and the Woodlands Institute. Involved in a health survey of a village in eastern Nepal as well as in developing a field clinic. April, 1983. GRANTS: Photocure Grant. Principal Investigator: David M. Albala, M.D. Principal Investigator: David M. Albala, M.D.: A Randomized, Comparative, Post- Market Evaluation of Symptoms and Discomfort Associated with an Indwelling Ureteral Stent. Awarded $7,000 by Boston Scientific Corporation, Natick, Massachusetts, February, 2001. Principal Investigator: David M. Albala, M.D.: Flow Characteristics of the Lithostent. Awarded $20,000 by ACMI/Circon, Inc., Norwalk, Connecticut, January, 2001. Principal Investigator: David M. Albala, M.D. : Vaginal Thermotherapy for the Treatment of Urinary Incontinence. Awarded $30,000 by SURX, Pleasanton, California, September, 2000. Principal Investigator: David M. Albala, M.D.: Medstone STS-T Lithotriptor. Awarded $25,000 by Medstone, Inc., San Francisco, California, May, 2000. Principal Investigator: David M. Albala, M.D.: Nephro-Step : A New Device for Percutaneous Access. Awarded $5,000 by Innerdyne, San Francisco, California, March 2000. Principal Investigator: David M. Albala, M.D.: A New Laparoscopic Procedure for the Treatment of Urinary Incontinence. Awarded $50,000 by SURX, Pleasanton, California, April, 1999. Principal Investigator: David M. Albala, M.D.: A New Ureteral Stent. Awarded $10,000 by ACMI/Circon Inc., Norwalk, Connecticut, February, 1998 Principal Investigator: David M. Albala, M.D.: Thermotherapy Treatment for Benign Prostatic Hypertrophy. Awarded $75,000 by Thermatrix, Chicago, Illinois, January, 1997. Principal Investigator: David M. Albala, M.D.: Laparoscopic Ureteral Reanastomosis using Fibrin Glue. Awarded $15,000 by The National Kidney Foundation of Illinois. Chicago, Illinois, November, 1992. Principal Investigator: David M. Albala, M.D.: Contact Nd: YAG Laser Prostatectomy in the Canine Model. Awarded $12,000 by Surgical Laser Technology, Oaks, Pennsylvania. June, 1992.
  • Principal Investigator: David M. Albala, M.D., Co-Investigator: Mansel Kevwitch, M.D.; Laparoscopic Ureteral Reanastomosis Awarded $5,000 by Ethicon Endosurgical Institute, Cincinnati, Ohio. March, 1992. Principal Investigator: Department of Community Health Sciences, Aga Khan University and Medical College; The Aga Khan University Scholars in Community Health Sciences: A Career Development Program for Physicians and Nurses in Pakistan. Co-authored with Dr. John Bryant. Awarded C $1,110,000 by the Canadian International Development Agency, Canada, for a four-year project. November 1986. Principal Investigator: Department of Community Health Sciences, Aga Khan University and Medical College; A Proposal for a Primary Health Care Pilot Program in the Northern Areas of Pakistan. Co-authored with Dr. John Bryant, Dr. Eugene Boostrom, and Ms. Shameela Karmali. Awarded US $302,467 by the Aga Khan Foundation, Geneva and USAID, Washington, D. C. for a two-year project. July, 1986. Principal Investigator: Department of Community Health Sciences, Aga Khan University and Medical College; A Proposal for Studying Health and Health Services and for Developing Initiatives in Thatta District. Co-authored with Dr. John Bryant. Awarded C $253,416 by the International Development Research Center, Canada for a three-year study. September, 1986. Principal Investigator: Department of Community Health Sciences, Aga Khan University and Medical College; The Sequential Development of Primary Health Care Modules in Katchi Abadies and Other Low Income Settlements of Urban Karachi. Co-authored with Dr. John Bryant. Awarded US $503,147 by the Aga Khan Foundation, Geneva, for a three-year study. February, 1986. RESEARCH PROJECTS: Principal Investigator: David M. Albala, M.D., Lower Pole II: A Prospective Randomized Trial of Ureteroscopy and Percutaneous Nephrostolithotomy for Lower Pole Nephrolitiasis. Study conducted at Loyola University Medical Center and Duke University Medical Center, 2000-present. Principal Investigator: David M. Albala, M.D., Flow Characteristics of the Lithostent. Study conducted at Loyola University Medical Center 2000 - 2001. Principal Investigator: David M. Albala, M.D., A Randomized, Comparative, Post- Market Evaluation of Symptoms and Discomfort Associated with an Indwelling Ureteral Stent. Study conducted at Loyola University Medical Center and other academic medical centers, 2000 - 2001.
  • Principal Investigator: David M. Albala, M.D., Medstone STS-T: A Multi-institutional Study. Study conducted at Loyola University Medical Center and other academic medical centers, 2000 - 2001. Principal Investigator: David M. Albala, M.D., Vaginal Thermotherapy for the Treatment of Urinary Incontinence. Study conducted at Loyola University Medical Center, 2000 - 2001. Principal Investigator: David M. Albala, M.D., Thermotherapy Treatment for Benign Prostatic Hypertrophy (Multi-Institutional Randomized Study). Study conducted at Loyola University Medical Center and other academic medical centers, 1998 - 2000. Principal Investigator: David M. Albala, M.D., Optimal Therapy for Middle and Distal Calculi (Multi-Institutional Randomized Study) Study conducted at LUMC and other academic medical centers, 1995 - 2000. Principal Investigator: David M. Albala, M.D., Lower Pole I: A Prospective Randomized Trial of Extracorporeal Shock Wave Lithotripsy and Percutaneous Nephrostolithotomy for Lower Pole Nephrolithiasis. Study conducted at Loyola University Medical Center and other academic medical centers, 1997 – 2000. Principal Investigator: David M. Albala, M.D., A New Laparoscopic Procedure for the Treatment of Urinary Incontinence. Study conducted at Loyola University Medical Center and other academic medical centers, 1999 - 2000. Principal Investigator: David M. Albala, M.D., Evaluation of a New Model Ureteral Stent. Study conducted at Loyola University Medical Center. 1999 - 2000. Principal Investigator: David M. Albala, M.D., Direx Tripter X1 Lithotripter: Fragmentation of Upper Urinary Stones. (FDA Trial - Project # 0051) Study conducted at LUMC, 1992-1996. Principal Investigator: David M. Albala, M.D., Leonard Gomella, M.D. and Douglas Milam, M.D.: Contact Nd: YAG Laser Prostatectomy in the Canine Model. (Surgical Laser Technology, Inc. Study #B243-0). Study conducted at LUMC, 1992-1993. Principal Investigator: David M. Albala, M.D. Fluoroscopically Controlled Incision of Upper Urinary Tract Strictures. (Applied Urology, Inc Study #C91-002) Study conducted at LUMC, 1991-1993. Principal Investigator: Stuart M. Selikowitz, M.D. Co-Investigator: David M. Albala, M.D. Informed Patient Decision-Making in Patients with BPH: Pilot Project. A pilot benign prostate hypertrophy informed patient decision-making program (IPDP) conducted at the Veterans Administration Hospital, White River Junction, VT, in conjunction with the Dartmouth Medical School Department of Community Medicine, 1989 - 1991.
  • Principal Investigator: John A. Heaney, M.D. Co-Investigator: David M. Albala, M.D. Phase III - Patient preference and quality of life in metastatic prostate carcinoma: Zoladex versus orchiectomy. (Stuart Pharmaceuticals ZOL - 7-624-3) - Study conducted at Dartmouth-Hitchcock Medical Center, 1987 - 1990. Principal Investigator: John A. Heaney, M.D. Co-Investigator: David M. Albala, M.D. Phase III - Long-term efficacy and safety of Terazosin in the treatment of the symptoms of benign prostatic hypertrophy. (Abbott Laboratory Protocol Number M87-006) - Study conducted at Dartmouth-Hitchcock Medical Center, 1987 - 1990. JOURNALS: EDITORIAL BOARD: Journal of Endourology – Editorial Board 2001 - present Urology Index & Reviews - Editor 1997 – present Current Opinion in Urology-Editorial Board 2001- present Techniques in Urology - Editor in Chief* 1994 – 2002 *Techniques in Urology was accepted in Medline in 1996, two years after its inception. JOURNALS: REVIEWER/ABSTRACTOR Urology 1994 - present Obstetrics and Gynecology 1994 - present Journal of Urology 1992- present Journal of Endourology 1990 - present Surgery, Gynecology, and Obstetrics 1990 – present British Journal of Urology 2000-present COURSES: PROGRAM DIRECTOR Hand Assisted Laparoscopic Urological Surgery—Duke University Medical Center, March 2002; April 2002; May 2002; June 2002; August 2002; September 2002; October 2002; November 2002; December 2002; January 2003; April 2003.
  • Urological Laparoscopy-American College of Surgeons Clinical Congress, October, 2001. Hand Assisted Laparoscopic Urological Surgery - Loyola University Medical Center, August, 2000; September, 2000; October, 2000; December 2000; January 2001; March, 2001; April, 2001; September, 2001. Management Strategies for the Treatment of UPJ Obstruction - American Urological Association, June, 1998; June 1999. New Horizons in Urology - Loyola University Medical Center; February, 1992; October, 1992; May, 1993. FACULTY Laparoscopic Urological Surgery—American Urological Association Annual Review Course (Chicago), March 2002; May 2003. Annual International Course on Urological Laparoscopic Surgery, Medical University of Ribeirao Preto, Brazil, July 2001; September, 2001. Hand-Assisted Laparoscopy- American Urological Association; February, 2001. Hand- Assisted Laparoscopic Urological Surgery - Ethicon Endosurgical Institute; November, 2000; May, 2001; October 2001; March 2002. Laparoscopic Urology - Brazilian Urological Association; November, 2000. Frontiers in Endourology - Washington University School of Medicine; June, 1991; June, 1992; July, 1994. Lasers and Laparoscopy in Urology - New Jersey Laser Institute; September, 1991. Laparoscopic Surgery - University of Minnesota Medical Center; October, 1991. Minimally Invasive Surgery - Thomas Jefferson Medical School; May, 1992; July, 1992; August 1995. Laparoscopic Surgery - Harvard Medical School; April, 1992. Laparoscopic Urology - Tulane University Medical School; November, 1991; February, 1992; May, 1992, March, 1993, September 1993, November 1994. Laparoscopy in Urology - New York University Medical School; December, 1991; March, 1992; June, 1992; December, 1992; May 1993, July 1994.
  • Laparoscopic Urology - Cornell University Medical Center; February, 1992; May, 1992; September, 1992, March, 1993; October, 1993; May, 1994. Laparoscopic Urology - Georgetown University Medical School; March, 1992. Laparoscopic Urology - Dartmouth-Hitchcock Medical Center; January, 1992. Laparoscopy - American Urological Association- October, 1992; May 1993, May 1994, January, 1995, May, 1995. Advanced Laparoscopy - American Urological Association; March, 1993. Lasers in Urology - Cornell University Medical Center, February, 1994; April, 1994. PUBLICATIONS: ARTICLES: Dahm, P., Paulson, D., and Albala, D.M.: Management of Retained Retractor During Radical Perineal Prostatectomy. Journal of Urology 159:1085, 2003. Albala, D.M., Turk, M.T., Fulmer, B.R., et al: Office -Based Transurethral Microwave Thermotherapy (TUMT) using the Thermatrix TMX-2000. Journal of Endourology 16:57, 2002. Fulmer, B., Sakamoto, K., Albala, D.M., et al.: Acute and Long-Term Outcome of Radiofrequency Bladder Neck Suspension. Journal of Urology 167:141, 2002. Fulmer, B.R., Turk, M.T. and Albala, D.M. : Editorial: Retroperitoneoscopic Adrenalectomy: Lateral Approach. Journal of Endourology 15:505, 2001. Sadowski, E.A., Salomon, C.G, Wojcik, E.M. and Albala, D.M.: Fibroma of the Testicular Tunics: An Unusual Extratesticular Intrascrotal Mass. Journal of Ultrasound Medicine 20:1245, 2001. Kumar, U. and Albala, D.M.: Laparoscopic Approach to Adrenal Carcinoma. Journal of Endourology 15: 339,2001. Albala, D.M., Assimos, D.G., Clayman, R.V. et al: Lower Pole I: A Prospective Randomized Trial of Extracorporeal Shockwave Lithotripsy and Percutaneous Nephrostolithotomy for Lower Pole Nephrolithiasis—Initial Results. Journal of Urology 166:2072, 2001. Kumar, U., Dickerson, A., Sakamoto, K., Albala, D.M., and Turk, T.M.T. : Effects of Fibrin Glue on Injured Rabbit Ureter. Journal of Endourology: 15: 205, 2001.
  • Kumar, U. and Albala, D.M.: Techniques in Intracorporeal Tissue Approximately: Suturing, Newer Tissue Adhesives and Microclips. Urologic Clinics of North America 28:15, 2001 Galen, D.I., Abbott, K., Albala, D.M. et al: Radiofrequency Bladder Neck Suspension: Long Term Results Using a Laparoscopic Approach. Obstetrics and Gynecology 97:49, 2001. Kumar, U. and Albala, D.M.: Fibrin Glue Applications in Urology. Current Urology Review, 2:79, 2001. Albala, D.M., Turk, M.T., Fulmer, B.R., et al: Periurethral Transurethral Microwave Thermotherapy (P-TUMT) for the Treatment of BPH: An Interim 1 year Safety and Efficacy Analysis Using the Thermatrix TMX - 2000. Techniques in Urology 6:288, 2000. Kumar, U. and Albala, D.M.: Simple Nephrectomy: Transperitoneal Approach. Journal of Endourology 14:10, 2000. Wolf, J.S., Marcovich, R., Albala, D.M. et al: Survey of Neuromuscular Injuries to the Patient and Surgeon During Urologic Laparoscopic Surgery. Urology 55:831, 2000. Albala, D.M., Rassweiler, J., Winfield, H.N. et al: Controversial Cases in Endourology. , Rassweiler, J., Winfield, H.N. et al: Controversial Cases in Endourology. Journal of Endourology 14:541, 200. Fulmer, B.R., Turk, M.T. and Albala, D.M.: Complications of Retrograde Balloon Cautery Endopyelotomy Journal of Urology 165: 542, 2000 Turk, T.M.T., Koleski, F., Wojcik, E., Jahoda, A., and Albala, D.M.: Use of Epidermal Growth Factor and Collegen Synthesis Inhibition As Adjuvant to Healing of Ureteral Anastomosis. Journal of Endourology 14:145, 2000. Koleski, F., Turk, T.M.T., Jahoda, A., and Albala,D.M.: Grooved Ureteral Stent: Preliminary Evaluation. Journal of Endourology 14:2, 2000. Koleski, F., Turk, T.M.T., and Albala, D.M.: Laparoscopic Adrenalectomy. AUA News 4:3, 1999. Koleski, F., Turk, T.M.T., Orwega, M., Borge, M., and Albala D.M.: Splenosis as a cause for Testicular pain - Laparoscopic Management. Journal of Endourology 13:373, 1999. Koleski, F., Turk, T.M.T, and Albala, D.M.: Update on Endourology and Laparoscopic Urology. Chicago Medicine 102:17, 1999.
  • Koleski, F., Turk, T.M.T., and Albala D.M.: Carcinosarcoma of the Prostate. World Journal of Urology 17:316, 1999 Albala, D.M.: Review of Campbells Urology, Doody’s Review 3:26, 1999 Turk,T.M.T., Koleski, F.C., and Albala D.M.: Incidence of Urolithasis in Cystectomy Patients after Intestinal Conduit or Continent Urinary Diversion. World Journal of Urology 17:305,1999 Jahoda, A.E., Albala, D.M., Dries, D.J., and Kovacs E.J.: Fibrin Sealant Inhibits Connective Tissue Deposition in a Murine Model of Peritoneal Adhesions. Surgery 125:53, 1999. Herrell, S.D., Jahoda, A.E., Husain, A.N., and Albala, D.M.: The Laparoscopic Cooling Sheath: A Novel Device for Hypothermic Preservation of the Kidney During Temporary Renal Artery Occlusion. Journal of Endourology 12:155, 1998. Gill, I.S., Clayman, R.V., and Albala D.M. et.al: Retroperitoneal and Pelvic Extraperitoneal Laparoscopy: An International Perspective, Urology 52:566, 1998 Kim, F.J., Herrell, S.D., Jahoda, A.E., Albala, D.M.: Complications of Acucise Endopyelotomy. Journal of Endourology 12:433, 1998. Gomella, C., Loft, M., Hirsch, I., Albala, D.M., Manyak, M., Sosa, E., and Stone, N.: Laparoscopic Urologic Surgery: Outcome Assessment. Journal of Laparoscopic and Advanced Surgical Techniques 7:77, 1997. Preminger, G.M., Clayman, R.V., Nakada, S.Y., Babayan, R.K., Albala, D.M., Fuchs, G.J., Smith, A.D. A multicenter clinical trial investigating the use of a fluoroscopically controlled cutting balloon catheter for the management of ureteral and ureteropelvic junction obstruction. Journal of Urology 157:1625, 1997. Gomella, L.G., Abdel-Meguid, T.A., Lofti, M.A., Hirsch, I.H., Albala, D.M., Manyak, M., Kozminski, M., Sosa, E., Stone, N.N. Laparoscopic Urologic Outcome Assessment. Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A. 7:77, 1997. Albala, D.M.: Contact Laser Vaporization of the Prostate for Benign Prostatic Hypertrophy. Monographs in Urology 8:92, 1997 Gerber, G., Jahoda, A., Bales, G., and Albala, D.M.: Transurethral Vaporization of the Prostate in the Treatment of Bladder Outlet Obstruction at Two University Hospitals. Techniques in Urology 3:25, 1997. Ferrer, F., MacGillivray, D., Malchoff, C., Albala, D.M., and Schickman, S.J.: Bilateral Laparoscopic Adrenalectomy for Adrenocorticotropic-Dependent Cushing’s Syndrome. Journal of Urology 157:16, 1997.
  • Mendoza, D., Neuman, R., Albala, D.M., Cohen, M., et al: Laparoscopic Complications in Markedly Obese Urologic Patients (A Multi-Institutional Review). Urology 48:562, 1996. Brown, J., Albala, D.M., and Jahoda, A.: Laparoscopic Surgery for Advanced Lesions. Seminars in Surgical Oncology 12:96, 1996. Albala, D.M., Brown, J., and Jahoda, A.J.: Laparoscopic Adrenalectomy. Seminars in Surgical Oncology 14:216, 1996. Seilkowitz S. and Albala, D.M.: A Method of Exposing the Vesicourethral Anastomotic Site During Radical Prostatectomy. Journal of Urology. 154:1461, 1995. Albala D.M., Jahoda, A.E., McKay, T.C., and Castelli, M.: Ureteral Reanastomosis Using Fibrin Glue. Journal of Pelvic Surgery 1:49,1995. Albala DM., Galal HA., and Gomella LA: Laparoscopic Pelvic Lymph Node Dissection for Prostate Cancer. Atlas of the Urologic Clinics of North America, 3:43, 1995. Kerbl, K., Clayman, R., McDougall, E.M., Gill, I.S., Wilson B.S., Chandhoke, P.S., Albala, D.M., Kavoussi, L.R.: Transperitoneal Nephrectomy For Benign Disease Of The Kidney: A Comparison of Laparoscopic And Open Surgical Techniques. Urology 43: 607,1994. Anderson, K., Keetch, D., Albala, D.M., Chandhoke, P., McClennan, B. and Clayman, R.V.: Optimal Therapy for the Distal Ureteral Stone: Lithotripsy vs. Ureteroscopy. Journal of Urology . 152:62, 1994. Gomella, L.G., Lotfi, M.A., Milam. V., Albala, D.M., and Reagan G: Contact Laser Vaporization Of The Prostate For Benign Prostatic hypertrophy. Progress in Biomedical Optics, 2129:73, 1994. Albala, D.M.: Laparoscopic Nephrectomy and Adrenalectomy. Seminars in Surgical Oncology 10:417, 1994. Gomella L.G., and Albala, D.M.: Laparoscopic Urology Surgery 1994. British Journal of Urology 74:267, 1994. Albala, D.M., Prien, E.L. and Galal, H.A.: Urolithiasis as a Hazard of Sulfonamide Therapy. Journal of Endourology 8:401, 1994. Albala, D.M., Richardson, J.R., and Heaney, J.A.: Diuretic Renal Scan: Is It Always Reliable. Journal of Endourology. 8:405, 1994.
  • Monk, T.G., Albala, D.M., Diaz, Y., Clayman, R.V., and White, C.F., Topical EMLA Analgesia: Effects on Pain Response and Analgesic Requirement During Lithotripsy Procedures. Anesthesia and Analgesia. 79:506, 1994. McKay, T.C., Albala, D.M. and Gehrin, B.: Laparoscopic Ureteral Reanastomosis Using Fibrin Glue. Journal of Urology 152:1637, 1994. McKay, T.M., Albala, D.M., Sendelbah, K. and Gattuso, P.: Cytomegalovirus Prostatitis: Case Report and Review of the Literature. International Urology and Nephrology. 26:535, 1994. Albala, D.M.: How to Approach the Problematic Ureteral Stone. Contemporary Urology 5:64,1993. Klutke, J. Kavoussi, L.R., Albala, D.M., and Clayman, R.V., Laparoscopic Treatment of Ureteral Obstruction Secondary to Ovarian Remnant Syndrome, Journal of Urology. 149:827, 1993. Kerbl, K., Figenshau, R., Clayman, R., Chandhoke, P., Kavoussi, L., Albala, D.M. and Stone, A.: Retroperitoneal Laparoscopic Nephrectomy: Laboratory and Clinical Experience. Journal of Endourology 7:23, 1993. Klutke, J., Kavoussi, L., Albala, D.M., Clayman, R.: Laparoscopic Treatment of Ureteral Obstruction Secondary to Ovarian Remnant Syndrome. Journal of Urology 149:827, 1993. Albala, D.M., Kevwitch, M.K. and Waters, W.B.: Treatment of Persistent Lymphatic Drainage after Laparoscopic Pelvic Lymph Node Dissection and Radical Retropubic Prostatectomy. Journal of Endourology 7:337, 1993. Kavoussi, L.R., Albala, D.M., and Clayman, R.V.: Outcome of Secondary Ureteropelvic Junction Obstruction Failures. British Journal of Urology 72:157, 1993. Gagner, M., Lacroix A., Prinz R., Bolter E., Albala, D.M. Potvin, C., and Hamet, P: Early Experience with Laparoscopic Approach for Adrenalectomy. Surgery 114:1120, 1993. Albala, D.M., Schuessler, W.W., and Vancaille, T.G.: Laparoscopic Bladder Neck Suspension. Journal of Endourology, 6:137, 1992. Clayman, R.V., Kavoussi, L.R., Soper, N.J., Albala, D.M., Figenshau, R.S., and Chandhoke, P.S. Laparoscopic Nephrectomy: Review of the Initial 10 Cases. Journal of Endourology 6:127, 1992. Chandhoke, P.S., Albala, D.M. and Clayman, R.V.: Long Term Comparison and Renal Function in Patients with Solitary and/or Renal Insufficiency Undergoing ESWL or Percutaneous Nephrolithotomy, Journal of Urology. 147:1226, 1992.
  • Clayman, R.V., Kavoussi, L.R., McDougall, E.M., Soper, N.J., Figenshau, R.S., Chandhoke, P.S. and Albala, D.M.: Laparoscopic Nephrectomy: A Review of 16 Cases. Surg. Laparoscopy and Endoscopy 2:29, 1992. Albala, D.M., Kavoussi, L.R., and Clayman, R.V: Laparoscopic Nephrectomy. Seminars in Urology, 10:146, 1992. Kavoussi, L.R., Albala, D.M., Basler, J.W., Apte, S. and Clayman, R.V.: Percutaneous Management of Urolithiasis During Pregnancy. Journal of Urology. 148:1069, 1992. Albala, D.M. Schuessler W.W., and Vancaillie, T.G.: Laparoscopic Bladder Suspension For The Treatment Of Stress Incontinence. Seminars in Urology 10:222, 1992. Meretyk S., Albala, D.M., Clayman R.V., Denstedt, J. and Kavoussi, L.R: Endoureterotomy For The Treatment Of Ureteral Strictures. Journal of Urology 147:1502, 1992. Albala, D.M.: Clayman, R.V.: Commentary: Percutaneous Nephrolithotomy An Approach to Branded and Staghorn Renal Calculi. Journal of Lithotripsy and Stone Disease, 3:182, 1991. Albala, D.M. and Richardson, J.R., Jr: Diagnosis and Treatment of Bladder Rupture: A Review of 42 Cases. Rhode Island Medical Journal, 74:133, 1991. Albala, D.M., Richardson, J.R., and Heaney, J.A.: Urological Injury and Assessment in Patients with Pelvic Fractures. Rhode Island Medical Journal, 74:128, 1991. Huntsman, W.T., and Albala, D.M.: Cardiac Tamponade as an Unusual Presentation of Lung Cancer: A Case Report and Review of the Literature. Clinical Cardiology, 14:529, 1991. Figenshau, R.S., Albala, D.M., Clayman, R.V., Kavoussi, L.R., Chandhoke, P.S., and Stone, A.M.: Laparoscopic Nephroureterectomy: Initial laboratory Experience, Minimally Invasive Therapy, 1:93, 1991. Albala, D.M., Meretyk, S. and Clayman, R.V.: Extracorporeal Shock Wave Lithotripsy (ESWL) for Ureteral Calculi: To Stint or Not to Stint, Journal of Endourology, 5:277, 1991. Albala, D.M., Chung, C.J., Sueoka, B.L., Memoli, V.A., and Heaney, J.A.: Hemorrhagic Myelolipoma of the Adrenal Gland After Blunt Trauma. Urology, 38:559, 1991. Clayman, R.V., Kavoussi,, L.R., Figenshau, R.S., Chandhoke, P.S., and Albala, D.M.: Laparoscopic Nephroureterectomy: Initial Clinical Case Report. Journal of Laparoendoscopic Surgery, 1:343, 1991.
  • Albala, D.M., Danaher, J., and Huntsman, W.T.: Ventriculoperitoneal Shunt Migration Into the Scrotum. The American Surgeon, 55:685, 1989. Albala, D.M. and Danaher, J.W.: Thank you, Sahib. Dartmouth Medical School Alumni Magazine, Winter 1987. Albala, D.M.: Primary Health Care in Bangkok. World Hospitals, 23:1, 1987. Albala, D.M., Faisel, A., Fikree, F. and Bryant, J.: The Educational Programs of the Aga Khan University Department of Community Health Sciences. Specialist, 2:25, 1986. Albala, D.M., Quershi, F.A. and Karim, M.S.: A Comparison of Health and Socioeconomic Indicators in the Townships of Orangi and Karimabad. Journal of Pakistan Medical Association, 36:9, 1986 Albala, D.M.: Healing the Sick in Pakistan, Special two-part article in The Valley News, West Lebanon, NH October 1986. Albala, D.M., Huntsman, W.T. and Crichlow, R.W.: Gallstone Ileus. Surgical Rounds, 8:93, 1985. Albala, D.M., and Taylor-Ide, D.: Water Quality and Diarrheal Diseases in a Rural Community of Eastern Nepal. Journal of the Institute of Medicine, 7:13, 1985. Albala, D.M., Bromley, B., Culver, J., et al: Medical Report from Isolated Communities in Sankhuwsabha District - Kosi Zone. Journal of the Institute of Medicine, 7:21, 1985. Albala, D.M.: The Spirit of Nepal. Lafayette College Alumni Magazine, Summer, 1985 Albala, D.M. and Schamel, S.: Water Quality of the Martins Creek Drainage Basin. Proceedings of the Pennsylvania Academy of Sciences, 53:101, 1979. SUBMITTED: Fulmer, B., Turk, T., Albala, D.M., et al.: Extracorporeal Shock Wave Lithotripsy with the Medstone STS-T (Transportable) Electrohydraulic Lithotripter: Experience with 370 Cases. Journal of Endourology. Albala, D.M., Del Guidice, P., Coombs, D.W., and Colburn, R.: Temporal Correlation Between Toxic Plasma and Urinary Inorganic Fluoride Levels and Urinary PGE2 in the Ewe. Canadian Journal of Anesthesia. Toselli, C.V., Fleming, C., Albala, D.M., and Selikowitz, S.M.: A Decision Analytic Approach to the Management of Clinical Stage I Non-Seminomatous Germ Cell Testicular Tumors. Techniques in Urology.
  • Griffin, J., Hatch, D. and Albala, D.M.: Laparoscopic Replacement of CAPD Catheters. Journal of Urology. Jahoda, J., Simon, S., Albala, D.M., et al.: Systemic Effects of Intraparenchymal Injection of Fibrin Sealant for Renal Lacerations. Journal of Urology. BOOKS (Editors) Atlas of Endourology Albala, D.M., and Grasso, M.,: (Eds.) Raven Press, New York, NY, 1999. Textbook of Endourology, Albala, D.M., Sosa, E.R., Perlmutter, A.B. and Jenkins, A., (Eds.), W. B. Saunders, Cambridge, Mass., 1996. BOOKS (Assistant Editor) Five Minute Urological Consult, Gomella, L.G. (Ed), Lippencott-Raven Press, New York, N.Y.,2000. Laparoscopic Urologic Surgery, Gomella, L.G., Kozminski, M., Winfield, H.N., (Eds.), Raven Press, New York, NY, 1993. BOOK CHAPTERS/MONOGRAPHS: Albala, D.M.: Laparoscopic Hand-Assisted Nephrectomy. Hemal, A.K. (Ed). Contemporary Trends in Laparoscopic Urologic Surgery, B.I. Churchill Livingston, New Delhi, 2002. Kumar, U. and Albala, D.M.: Fibrin Sealants in Urology. Minimally Invasive Therapies in Urology, Marcel Decker, New York, 2001. Martins, A.C. and Albala, D.M.: Prostate and Hormones. Martins, A.C. (Ed) Benign Prostate Diseases, FAEPA – Hospital das Clinicas de Ribeirao Preto, Ribeiro Preto, Brazil, 2001. Koleski, F.C. and Albala, D.M.: Acute Urinary Retention. Mulhall, J.P. (Ed). Contemporary Diagnosis and Management of Urologic Emergencies, Handbooks in Health Care Co., Newtown, Pennsylvania, 2001. Koleski, F.C. and Albala, D.M.: Laparoscopia Equipamento Castilho, L.C. (Ed). Laparoscopia Urologica. LPC Comunicacoes, Sao Paulo, Brazil, 2000. Koleski, F.C. and Albala, D.M.: Cirurgia do Ureter. Castilho, L.C. (Ed). Laparoscopia Urologica, LPC Comunicacoes, Sao Paulo, Brazil, 2000.
  • Kumar, U. and Albala, D.M.: Radionucleotide Imaging. Levine, D. (Ed) Urology Pearls of Wisdom Boston Medical Publishing, Boston, Mass., 2000. Kumar, U. and Albala, D.M.: Urinary Tract Infections. Levine, D. (Ed) Urology Pearls of Wisdom Boston Medical Publishing, Boston, Mass., 2000. Kumar, U. and Albala, D.M.: Urinary Tract Obstruction. Levine, D. (Ed) Urology Pearls of Wisdom Boston Medical Publishing, Boston, Mass., 2000. Albala, D.M., and Koleski, F.: Nephrolithiasis. Gomella, L.G. (Ed). Five Minute Urology Consult, Raven-Lippencott Press, New York, N.Y., 2000. Albala, D.M.: Backpacking to the Capital. McCrea Curnen, M., Spiro, H., and St. James, D. (Eds) Doctors Afield Yale University Press, New Haven, Ct., 1999. Kumar, U. and Albala, D.M.: History of Laparoscopy and Laparoscopic Instrumentation. Hemal, A.K. (Ed). Laparoscopic Surgery in Urology, B.I. Churchill Livingstone, New Delhi, India, 1999 Kumar, U. and Albala, D.M.: Hand Assisted Laparoscopic Surgery in Oncology. Hemal, A.K. (Ed). Laparoscopic Surgery in Urology, B.I. Churchill Livingstone, New Delhi, India, 1999 Albala, D.M.: Laparoscopic Adrenalectomy. In Glenn, J (Ed). Urologic Surgery, J.B. Lippincott, Philadelphia, PA, 1998. Albala, D.M.: Laparoscopic Adrenalectomy. In Albala, D.M., Sosa, E.R., Perlmutter, A.B and Jenkins, A., (Eds) Textbook of Endourology. W.B. Saunders, Cambridge, Mass, 1996. Albala, D.M., and Isacksen, R.: Laparoscopic Bladder Neck Suspension. In Albala, D.M., Sosa ER, Perlmutter, AB., and Jenkins A., (Eds). Textbook of Endourology. W.B. Saunders, Cambridge, Mass, 1996. Albala, D.M., and Brown JP: Endopyelotomy For The Treatment Of Ureteropelvic Junction Obstruction. In Rous, S.N. (Ed) 1995 Urology Annual East Norwalk, CT Appleton & Lange 1995. Albala, D.M.: Laparoscopic Adrenalectomy, In Smith, A.J. (Ed) Smith=s Endourology Textbook, St. Louis, Quality Medical Publish, Inc. 1995. Isacksen, R., Albala, J.C., Jahoda A.E., and Albala, D.M.: Legal Issues in Laparoscopy In Smith, A.J., (Ed) Smith=s Endourology Textbook. St. Louis, Quality Medical Publish, Inc. 1995.
  • Albala, D.M., Chandhoke, P.S., and Clayman, R.V.: Ureterorenoscopy: Urolithiasis. In Krane, R., Siroky, M., and Fitzpatrick, J. (Eds.) Clinical Urology. Philadelphia, PA: J.B. Lippincott Company, 1994. Albala, D.M.: Postoperative Laparoscopic Care. In Soper, N., Oden, R., Clayman, R. and McDougal, E. (Eds.) Essentials of Laparoscopy St. Louis: Quality Medical Publishing, Inc., 1994. Albala, D.M.: Laparoscopic Nephrectomy. In Steichen F.M., Welter R, (Eds.) Minimally Invasive Surgery and New Technology. St Louis: Quality Medical Publishing, Inc., 1994. Albala, D.M.: Vesicoureteral Reflux in Adults. In Seidmon, J., Hanno, P. and Kaufman, J. (Eds.), Current Urologic Therapy, W.B. Saunders Company, Cambridge, Mass., 1993. Albala, D.M.: Laparoscopic Surgery in Urology. In Roig, JMS (Eds.) Progress in Urology 1993. Barcelona, Spain: Support Med Publishing, 1993. Albala, D.M. and Prinz, R.: Retroperitoneal Evaluation and Resection of Adrenal Masses. In Rosin, D. and Greene, F. (Eds.) Minimal Access Surgical Oncology. Radcliffe Medical Press, New York, NY, 1993 Albala, D.M.: Preparing for an International Meeting. In St. James, D. (Ed.), Writing and Speaking for Excellence: A Practical Guide for Physicians, Jones and Bartlett, Boston, Mass., 1993. Albala, D.M.: Stenting Prior to ESWL - Complications. In Smith, A.D. (Ed.) Controversies in Endourology, W.B. Saunders Company, Cambridge, Mass., 1993. Albala, D.M. and Kavoussi, L.R.: Laparoscopic Ureteral Surgery. In Das, S. and Crawford, D., (Ed.) Laparoscopic Urology, Orlando, FL, W. B. Saunders Company, 1993. Albala, D.M., Vancaille, T.G., and Schuessler, W.W.: Suspension of the Bladder Neck Using the Laparoscope. In Gomella, L., Kozminski, M. and Winfield, H. (Eds.) Laparoscopic Urologic Surgery, New York, N.Y., Raven Press, 1993. Albala, D.M.: Postoperative Laparoscopic Care. In Clayman, R. and McDougall, E., (Eds.) Laparoscopic Urology, St. Louis, MO, Quality Medical Publishers, 1992. Meretyk, S., Albala, D.M., Kavoussi, L., and Clayman, R.V.: Endosurgery: Non- Calculus Applications in the Upper Urinary Tract. In Stamey, T.A. (Ed.) Monographs in Urology. Montverde, FL: Medical Directions Publishing Company, 1991, Volume 12, No. 4.
  • Albala, D.M., Prien, E.L., Jr., and Heaney, J.A.: Drug-Induced Urinary Lithiasis. In Rous, S.N. (Ed.) 1990 Urology Annual. East Norwalk, CT., Appleton & Lange, 1990, pp. 255-266. VIDEOTAPES: Fulmer, B.R., Turk, T.M.T. and Albala, D.M.: Nephro-Step for Percutaneous Access (10 minutes), 2001 Albala, D.M.: Urological Laparoscopy: Hand-Assisted Nephrectomy, Adrenalectomy and Radical Prostatectomy. (15 minutes), 2001. Fulmer, B.R., Turk, T.M.T. and Albala, D.M.: Hand - Assisted Nephrectomy using the Intromitt. (10 minutes), 2000. Albala, D.M., Turk, T.M.T. and Fulmer, B.R.: Nephro-Step: A New Device for Percutaneous Access. (8 minutes), 2000. Kumar, U., Dickerson, A. and Albala, D.M.: Transurethral Resection of the Prostate using the Marberger Loop. (8 minutes), 2000. Albala, D.M., Turk, T.M.T., and Koleski, F.: Percutaneous Nephrolithotomy: Our Surgical Technique (10 minutes), 1999. Albala, D.M., and Thomas, R.: Laparoscopic Adrenalectomy: A Step-by-Step Approach (12 minutes), 1997. Herrell, D., Jahoda, A., and Albala, D.M.: The Use of Fibrin Glue in Urology (14 minutes), 1996. Albala, D.M. and Jahoda A.J.: Electrosurgical Vaporization of the Prostate - A New Procedure (10 minutes), 1995. Albala, DM and Flanigan, RF: Laparoscopic Adrenalectomy. American College of Cine Clinics (14 minutes), 1994. Isacksen, RM, Jordan G, Albala, DM, and Winslow, B: Laparoscopy in Children (10 minutes), 1994 Albala, D.M. and Prinz, R.: Laparoscopic Adrenalectomy, Video Journal of General Surgery, Volume 2, No. 1, (12 minutes), 1993. Asbury, J.A. and Albala, D.M.: Laparoscopic Renal Cyst Surgery (9 minutes), 1993. Isacksen, R.M. and Albala, D.M.: The Role of Laparoscopy in Undescended Testes. (8 minutes), 1993.
  • McKay, T. and Albala, D.M.: Laparoscopic Ureteral Reanastomosis Using Fibrin Glue (9 minutes), 1993. Albala, D.M. and Prinz, R.: Laparoscopic Adrenalectomy for Cushings Disease (10 minutes), 1993. Albala, D.M. and Prinz, R.: Laparoscopic Adrenalectomy (8 minutes), 1992. Kinzler, G.J. and Albala, D.M.: Laparoscopic Drainage of the Post Transplant Lymphocele (10 minutes), 1992. Albala, D.M. and Kinzler, G.J.: Laparoscopic Placement of a Difficult Continuous Ambulatory Peritoneal Dialysis (CAPD) Catheter (9 minutes), 1992. Albala, D.M., Kevwitch, M.K. and Gehrin, B.: Acucise Endopyelotomy - A New Surgical Procedure (9 minutes), 1992. Kavoussi, L.R., Clayman, R.V., Figenshau, R.S., Soper, N.J., Chandhoke, P.S. and Albala, D.M.: Laparoscopic Nephrectomy: Initial Clinical Experience with a New Surgical Technique, (10 minutes), 1992. Kavoussi, L.R., Albala, D.M, and Clayman, R.V., Laparoscopic Ureterolysis, (10 minutes), 1992. Albala, D. M., Figenshau, R.S., Chandhoke, P.S., Kavoussi, L.V., and Clayman, R.V.: Potential Complications of Laparoscopic Surgery, (10 minutes), 1991. Kavoussi, L.V., Albala, D.M., and Clayman, R.V.: Laparoscopic Ureterolysis, A New Surgical Approach (8 minutes), 1991. Kavoussi, L.V., Albala, D.M., and Figenshau, R.S., and Clayman, R.V., Organ Entrapment Systems for Tissue Removal, (9 minutes), 1991. Chandhoke, P.S., Clayman, R.V., Albala, D.M., Figenshau, R.S. and Kavoussi, L.R.: Acucise Endopyelotomy: Initial Clinical Experience (10 minutes), 1991. Figenshau, R.S., Clayman, R.V., Kavoussi, L.R., Chandhoke, P.S., and Albala, D.M.,: Laparoscopic Nephrectomy, (12 minutes), 1990. Kavoussi, L.R., Clayman, R.V., Albala, D.M, Chandhoke, P.S., Figenshau, R.S, and Stone, A.M., Laparoscopic Nephrectomy, (10 minutes), 1990. Albala, D.M., Chandhoke, P.J., Figenshau, R.S., and Clayman, R.C.: Clinical Applications of Flexible Ureteronephroscopy (11 minutes) 1990.
  • OPERATIVE DEMONSTRATIONS: St. Petersburg Hospital, St. Petersburg, Florida—Laparoscopic Hand-Assisted Nephrectomy, December 2002 Baptist Hospital, Louisville, Kentucky—Laparoscopic Hand-Assisted Nephrectomy, November 2002 Champlain Valley Physician’s Hospital, Plattsburg, New York—Laparoscopic Hand- Assisted Nephrectomy, May 2002. Louisville General Hospital, Louisville, Kentucky—Laparoscopic Hand-Assisted Nephrectomy, May, 2002 Medical College of Virginia, Richmond, Virginia—Laparoscopic Hand-Assisted Nephrectomy, April, 2002 All India Institute of Medical Sciences, New Delhi, India—Laparoscopic Hand-Assisted Nephrectomy, April, 2002 Singapore General Hospital, Singapore - Laparoscopic Hand-Assisted Nephrectomy, September, 2001 University of Ribeirao Preto, Brazil – Laparoscopic Hand-Assisted Nephrectomy, July, 2001. Keesler Air Force Hospital, Biloxi, Mississippi – Bilateral Laparoscopic Hand-Assisted Nephrectomy, July, 2001. Ankara General Hospital, Ankara, Turkey – Accucise Endopyelotomy, May,2001. Caligary Hospital, Caligary, Sardenia, Italy – Laparoscopic Hand-Assisted Nephrectomy, Accuccise Endopyelotomy, May, 2001. Peoria Medical Center, Peoria, Illinois - Laparoscopic Hand-Assisted Nephrectomy, January, 2001. Iceland Urological Association, Reykjavik, Iceland - Laparoscopic Hand- Assisted Nephrectomy, October, 2000. 18th World Congress on Endourology and ESWL 16th Basic Research Symposium, Sao Paolo, Brazil- Acucise Endopyelotomy, September, 2000. Rhine Medical Center, Lepitz Germany - Laparoscopic Andrenalectomy, June, 2000.
  • Coimbatore Urological Association, Coimbatore, India - Laparoscopic Hand-Assisted Nephrectomy, June, 2000. All India Institute of Medical Sciences, New Delhi, India - Laparoscopic Hand-Assisted Nephrectomy, November, 1999. Lake Charles Medical Center, Lake Charles, Louisiana - Laparoscopic Adrenalectomy, July, 1999. San Diego Naval Hospital, San Diego, California - Laparoscopic Hand-Assisted Nephrectomy, July, 1999. Panipat Medical Center, Panipat, India - Ureteroscopy, Percutaneous Nephrolithotomy, December, 1998. All India Institute of Medical Sciences, New Delhi, India - Ureteroscopy, Endopyelotomy, December, 1998. Christian Medical College and Hospital, Vellore, India - Ureteroscopy, Endopyelotomy, Laparoscopic Nephrectomy, December, 1998. Tulane University Medical Center, New Orleans, Louisiana - Laparoscopic Adrenalectomy, October, 1997. George Washington University Medical Center, Washington D.C. - Laparoscopic Nephrectomy, April, 1996. Cornell University/New York Hospital, New York, New York - Laparoscopic Adrenalectomy, December, 1995. National Institute of Health, Bethesda, Maryland - Laparoscopic Adrenalectomy, March, 1995. Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire - Laparoscopic Pelvic Lymph Node Dissection, October 1994. Medical College of Wisconsin, Milwaukee, Wisconsin - Laparoscopic Pelvic Lymph Node Dissection, September, 1994. Hospital La Fe, Barcelona, Spain - Laparoscopic Nephrectomy, September, 1992. University of California at San Diego, San Diego, California - Ureteroscopy, Laparoscopic Pelvic Lymph Node Dissection, October, 1992. Cochin Hospitaux, Paris, France - Laparoscopic Nephrectomy, September, 1992.
  • Massachusetts General Hospital, Boston, Massachusetts - Laparoscopic Nephrectomy, August, 1992. INVITED PRESENTATIONS: Duke Winter Urologic Forum, Steamboat Springs, Colorado, February, 2003. 14th Annual Urology Symposium, Fort Lauderdale, Flordia, February, 2003. International College of Surgeons Meeting, Taipei, China, November, 2002. 20th World Congress on Endourology and ESWL, Geneva, Italy, October 2002. New York American Urological Association Annual Meeting, Madrid, Spain, September, 2002. All India Institute of Medical Science, New Delhi, India, April, 2002. Mexican Urological Association Annual Meeting, Mexico City, Mexico, February 2002. 19th World Congress on Endourology and ESWL, Bangkok, Thailand, November 2001. Singapore General Hospital, Singapore, September, 2001. Society of Pelvic Surgeons, Oslo, Norway, July, 2001. University of Rebeirao Preto, Rebeirao Preto, Brazil, July, 2001. 96th American Urological Association Annual Meeting, Anaheim, California, June, 2001. Ankara Urological Association, Ankara, Turkey, May, 2001. Italian Urological Association, Caligary (Sardinia), Italy, May 2001. Henry Ford Hospital (Grand Rounds), Detroit, Michigan, March 2001 Wayne State University (Grand Rounds), Detroit, Michigan, March 2001 Fourth International Symposium on Urology, Nephrology and Transplantation, Sindh Institute of Urology and Transplantation, Karachi, Pakistan, February, 2001. 48th Annual James C. Kimbrough Urological Seminar, San Diego, California, January, 2001. Societe of International Urology, Singapore, November, 2000.
  • The Mellineum Urological Meeting, Delhi, India, November, 2000. The 27th Annual Egyptian Urological Meeting, Cairo, Egypt, October, 2000. Iceland Urological Association, Reykjavik, Iceland, October, 2000. 18th World Congress on Endourology and ESWL, Sao Paolo, Brazil, September, 2000. Coimbatore Urological Association, Coimbatore, India, June, 2000. 95th American Urological Associates Annual Meeting, Atlanta, Georgia, May, 2000. Video Urology 2000: 12th World Congress of Videourology, Goa, India, March, 2000. All India Institute of Medical Sciences, New Delhi, India, November, 1999. Kentucky Urological Association , Louisville, Kentucky, November, 1999. Circon/ACMI Annual Meeting, Tampa, Florida, November, 1999. 17th World Congress of Endourology of Shock Wave Lithotripsy, Athens, Greece, September 1999. Specialty Review in Urology, Chicago, Illinois, April 1993, 1994, 1995, 1996, 1997,1998, 1999, 2000, 2001. Timely Topics in Urology, Loyola University, Maywood, Illinois, June 1999. 94th American Urologic Association Annual Meeting, Dallas, Texas, April, 1999. 23rd Annual James McDonald Urological Seminar, Scottsdale, Arizona, March 1999. University of Miami, Challenging Cases in Urology, Miami Florida, February, 1999. All India Institute of Medical Sciences, New Delhi, India, December, 1998. Christian Medical College and Hospital, Vellore, India, December, 1998. 16th World Congress of Endourology of Shock Wave Lithotripsy, New York, New York, September, 1998 Wayne State University Grand Rounds, Detroit, Michigan, August, 1998. Mississippi/Alabama Urological Society Meeting, Biloxi, Mississippi, August, 1998. 93rd American Urological Association Annual Meeting, San Diego, California, May 1998
  • Tampa Urological Association Meeting, Tampa, Florida, March, 1998. American College of Surgeons 84th Clinical Congress, American College of Surgeons, Orlando, Florida, October, 1998. 15th World Congress of Endourology and Shock Wave Lithotripsy, Edinburgh, Scotland, September, 1997. 92nd American Urologist Association Annual Meeting, New Orleans, Louisiana, April, 1997. The 44th Annual James C. Kimbrough Urological Seminar, Scottsdale, Arizona, December, 1996. The 1st International Pan Arab Endolaparoscopic Urology Congress, Cairo, Egypt, November, 1996. 14th World Congress of Endourology and Shock Wave Lithotripsy, Melbourne, Australia, November, 1996. American College of Surgeons - 82nd Clinical Congress, American College of Surgeons, San Francisco, California, October, 1996. North Central American Urological Association Annual Meeting, Tucson, Arizona, September, 1996. Alumni Meeting of the White House Fellows, Annapolis, Maryland, June, 1996 George Washington University Trauma Lecture, Washington DC, February, 1996. University of California San Diego - Tissue Sealants: Current Practice, Future Uses. San Diego, California, April, 1995. Uniformed Services University of the Health Sciences - Potential Uses of Fibrin Sealants, Bethesda, Maryland, December, 1994. 13th World Congress of Endourology and Shock Wave Lithotripsy, Jerusalem, Israel, November, 1995. Alf H. Gunderson Memorial Lecture, Gunderson Clinic, LaCrosse, Wisconsin, September, 1995 90th American Urological Association Meeting, Las Vegas, Nevada April, 1995. XII Annual Urology Conference, Gainesville, Florida, March 1995.
  • 12th World Congress of Endourology and Shock Wave Lithotripsy, St. Louis, Missouri, December 1994. American College of Surgeons - 80th Clinical Congress, Chicago, Illinois, October, 1994. North Central American Urological Association Annual Meeting, Boca Raton, Florida, September, 1994. Society of Pelvic Surgeons Annual Meeting, Chicago, Illinois, September, 1994. Basic Science Course in Urology, American Urological Association Charlottesville, Virginia, June, 1993; June, 1994; June 1995, June 1996, June 1997, June 1998, June 1999. 91st American Urological Association Meeting, San Francisco, California, May 1994. 5th Internal Meeting - Society for Minimally Invasive Therapy, Orlando, Florida, November, 1993. 11th World Congress on Endourology and ESWL, Florence, Italy, October, 1993. 35th World Congress of International Society of Surgery, Hong Kong, August 1993. Urological Association of Pennsylvania and Maryland Urological Society - New Technologies in Urology, Baltimore, Maryland June, 1993. 90th American Urological Association Meeting, San Antonio, Texas May, 1993. 17th Annual Clinical Problems in Urology, Northwestern University Chicago, Illinois, April, 1993. Society of Surgical Oncology Annual Meeting, Los Angeles, California, March, 1993. Curso Internacional - Advances in Urologia, Hospital La Fe, Barcelona, Spain, March, 1993. Minimally Invasive Surgery in Oncology Symposium, M.D. Anderson Cancer Center, Houston, Texas, December, 1992. Surgical Grand Rounds, Cornell University - New York Hospital, New York, N.Y., December, 1992. Hospital Universitario De Caracas, Caracas, Venezuela, November, 1992. Society for Minimally Invasive Therapy: 4th International Meeting, Dublin, Ireland. November, 1992.
  • American College of Surgeons - 78th Clinical Congress, New Orleans, Louisiana, October, 1992. San Diego Urological Society, San Diego, California, October, 1992. Minimally Invasive Surgery and New Technology. 2nd European Congress of Viscero - Synthesis, Luxemburg, September, 1992. 10th World Congress on Endourology and ESWL, Singapore, September, 1992. Group Hospitalier - Cochin, Hospitaux de Paris, Paris, France, June, 1992. 90th American Urological Association Annual Meeting, Washington, DC., June 1992. American Lithotripsy Society Annual Meeting, Orlando, Florida, October 1991. Society for Minimally Invasive Therapy: 3rd International Meeting, Boston, Massachusetts, June, 1991. Curso Internacional - Advances en Urologia, Hospital La Fe, Valencia, Spain, March, 1992. Videourology 91: 3rd World Congress of Videourology, Hakone, Japan, July, 1991. 9th World Congress on Endourology and ESWL, Vienna, Austriam, June 1991. 89th American Urological Association Annual Meeting, Toronto, Canada, June, 1991. International Anesthesia Research Society Meeting, San Antonio, Texas, April, 1990. Society for Medical Decision Making Boston, Massachusetts, March 1990. 88th American Urological Association Annual Meeting, New Orleans, Louisiana, May 1990. New England Section of the American Urological Association, Bermuda, October, 1988. New England Section of the American Urological Association, Montreal, Canada, October. 1997. Tri-State Meeting of the Maine, Vermont and New Hampshire Chapters of the Americal College of Surgeons, Sugarloaf, Maine, February, 1987. 1st Annual Symposium of the Abbassi Shaheed Hospital, Karachi, Pakistan, February, 1986.
  • 116th Annual American Public Health Association Meeting, Las Vegas, Nevada, November, 1986. 23rd Annual Symposium of the Jinnah Postgraduate Medical Center, Karachi, Pakistan, November, 1985.
  • Appendix C: Curriculum Vitae of Lesley Curtis DUKE UNIVERSITY MEDICAL CENTER CURRICULUM VITAE for Permanent Record and the Appointments and Promotions Committee Date Prepared: June 16, 2003 (Use “NA” for no entry and use continuation pages when necessary) Name (complete with degrees): Lesley H. Curtis, Ph.D., M.S. Primary academic appointment: Assistant Research Professor, Center for Clinical and Genetic Economics Director of CERTs Data Center Duke Clinical Research Institute, Duke University Medical Center Primary academic department (not DUAP): Medicine Secondary appointment (if any) - (department): NA Social Security number: 512-74-0681 Present academic rank and title (if any): Assistant Research Professor Date and rank of first Duke Faculty appointment: April 1, 2003 Medical Licensure: North Carolina License # NA Date of License (Month/Day/Year) NA Specialty certification(s) and dates (Month/Day/Year): NA Date of birth: August 13, 1965 Place (include city/state/country): Madison/ WI/ USA Citizen of : United States
  • Visa status (if applicable) Education: Institution Date (Year) Degree High School Topeka West High School 1983 Diploma College Washington University, B.A. 1987 B.A. Graduate or Professional School University of Rochester 1991 M.S. University of Rochester 2000 Ph.D.
  • -2- Scholarly societies (Alpha Omega Alpha, Sigma Xi, Phi Beta Kappa; etc.): NA Professional training and academic career (chronologically, beginning with first postgraduate position): Institution Position/Title Dates Federal Reserve Bank of St. Louis Systems Analyst 1986-1989 Academic Medical Center Consortium Program Director 1991-1996 University of Rochester Associate Provost 1996-2000 Duke Clinical Research Institute Director/CERTS 2000-Present Duke Clinical Research Institute Research Associate 2000-2003 Duke University School of Medicine Assistant Research Professor 2003-Present Publications: (Do not include submitted papers or papers in preparation. List separately those papers in press.) PLEASE NUMBER ALL ENTRIES SEQUENTIALLY (#1 OLDEST) 1. Nash IS, Curtis LH, and Rubin HR. (1999). Predictors of patient-reported physical and mental health 6 months after percutaneous coronary revascularization. American Heart Journal, 138:422-429. 2. Weaver CH, Buckner CD, Curtis LH, Bajwa K, Weinfurt KP, Wilson-Relyea BJ, and Schulman KA. (2002). Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. Bone Marrow Transplant, 29:159-164. 3. Curtis LH, Phelps CE, McDermott, MP, and Rubin, HR. (2002). The value of patient-reported health status in predicting short-term outcomes after coronary artery bypass graft surgery. Medical Care, 40(11):1090-1100.
  • 4. Seils, DM, Castel, LD, Curtis, LH, and Weinfurt, KP. (2002). Welfare reform and latinas' use of perinatal health care. American Journal of Public Health, Housing and Health. 92(5):699-700. 5. Al-Khatib SM, Allen LaPointe NM, Curtis LH, Kramer JM, and Califf RM. (2003). Outpatient Prescribing of Antiarrhythmic Drugs from 1995 through 2000. American Journal of Cardiology, 91:91-94. 6. Castel LD, Timbie JW, Sendersky V, Curtis LH, Feather KA, and Schulman KA. (2003). Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care. BMC Health Serv Res. 3(1). 7. Curtis LH, Østbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, Yasuda SU, Dans PE, Wright A, Califf RM, Woosley RL, and Schulman KA. (2003). Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. American Journal of Medicine, 114:135-141. 8. In Press Publications: 1. Sloan FA, Trogdon JG, Curtis LH, and Schulman KA. (2003). The impact of dementia on outcomes and process of care for medicare beneficiaries admitted with acute myocardial infarction. Journal of the American Geriatrics Society. Refereed journals: (Refereed journals are scientific publications that have active editorial boards and a system of critical review of all submissions for publication.) Non-refereed publications: (Non-refereed publications refer to those which do not routinely use a system of critical review prior to publication; such articles are often solicited by the publisher.) Chapters in books: 1. Rothenberg BM, Mooney C, and Curtis LH. Measures of severity of illness and comorbidity. Assessing the Health Status of Older Adults. Springer Publishing Company, Inc. New York, NY. August 1997.
  • Books: (Indicate authors or editor.) Non-authored publications: (Faculty member formally acknowledged in the publication for his/her contributions.) Other: a. Published scientific reviews (for mass distribution) b. Selected abstracts 1. Development of a method to increase power in economic analyses of multinational trials. Friedman JY, Weinfurt KP, Curtis LH, Gnanasakthy A, and Schulman KA. Quality of Care and Outcomes Research in CVD and Stroke, American Heart Association, October, 2002. 2. Physician characteristics of the Navigator trial predict average length of stay (ALOS) in acute coronary syndrome (ACS). Friedman JY, Curtis LH, Gnanasakthy A, and Schulman KA. International Society for Pharmaceutical Outcomes Research, 5th Annual European Congress, November, 2002. 3. Pharmaceutical expenditures in the elderly. Law AW, Curtis LH, and Schulman KA. Drug Information Association, 4th Annual Pharmaceutical Outcomes Research, Newport, RI, USA, October, 2002. 4. Yancy WS, Curtis LH, Schulman KA, Olsen MK, Cuffe M, Oddone G. (2003). Variations in coronary procedure utilization depending on body mass index. J Parenter Enteral Nutr 27(1):S12. c: Editorials, position, and background papers Editorials: 1. Welfare reform and Latinas’ use of perinatal health care. Seils DM, Castel LD, Curtis LH, and Weinfurt KP. Am J Public Health. 2001 Nov; 91(11):1857-64. Poster Presentations: 1. The impact of welfare reform on hospital expenditures for uncompensated care. Castel LD, Curtis LH, Timbie JW, Sendersky V, Feather KA, and Schulman KA. 2002 Annual Research Meeting of the Academy for Health Services Research and Health Policy. Washington DC, June, 2002. Panels:
  • 1. “Improving patient safety: health systems reporting, analysis, and research demonstrations.” Curtis, LH (panel participant). Agency for Healthcare Research and Quality, 2001. 2. “Maximizing the rational use of therapeutics: showcasing the centers for education and research in therapeutics (CERTs).” Curtis LH, Hennessy S, Shatin D, Chan KA. Drug Information Association, June 16-20, 2002, Chicago, IL. Invited Presentations: 1. Pooling outcomes data: The QMMI Experience. State-of-the-Art Health Outcomes Conference. Boston, MA. June, 1995. 2. Applying outcomes research to clinical practice. New England Healthcare Assembly. Boston, MA. April, 1995. 3. Measuring performance and quality in 12 academic medical centers. University of Rochester School of Medicine. Rochester, NY. March, 1995. 4. Maximizing the rational use of therapeutics: centers for education and research on therapeutics. American Public Health Association. Atlanta, GA. June, 2002. Consultant appointments: (Include US government, state, private organizations, etc.) NA Professional awards and special recognitions: NA Organizations and participation: (Offices held, committee assignments, etc.) NA Teaching responsibilities including continuing education: see attached Areas of research interests (basic and applied) - list: Pharmacoepidemiology Health Policy Outcomes Research
  • -4- External support - gifts, grants, and contracts: EXTERNAL SUPPORT Past Support PI % Effort Purpose Approx. Amount Duration N/A Present Support PI % Effort Purpose Approx. Duration Amount Kramer 9% Investigate clinical $519,480 9/29/02 – therapeutics in 9/28/07 cardiovascular medicine Califf .5% Enhance the $259,739 9/30/02 – CERTs 9/29/07 infrastructure and communications system Califf 35% Improve the $49,701 10/1/02 – detection of 3/31/03 medication prescribing errors in the ambulatory setting Califf 50% Enhance the $259,739 9/30/02 – CERTs 9/29/07 infrastructure and communications system Pending Support+ PI % Effort Purpose Approx. Duration Amount
  • Clinical activity - type of practice and estimate of time commitment: Participation in academic and administrative activities of the University and Medical Center _________________________________________________________________ _ Date Signature of Chair -5- Personal Information Faculty member’s preferred familiar name: Lesley H. Curtis Local home address: 305 Spring Garden Drive Durham, NC 27713 Local home phone # 919-806-1577 Marital status: Married Name of spouse: Brent
  • Appendix D: Curriculum Vitae of Jeffrey Sung JEFFREY SUNG 103 Mayfield Circle (919) 395-1001 Durham, NC 27705 jeffrey.sung@duke.edu Education 2000.2005 DUKE UNIVERSITY, School of Medicine and The Fuqua School of Business, Durham, NC Candidate for the degrees of Doctor of Medicine and Master of Business Administration, May 2005. Honors: Albert Schweitzer Fellow, Marshall and Sarah Pickens Scholarship Medical School Admissions Committee (Interviewer). Alternative Career Paths in Medicine (Founder). Christian Medical and Dental Association (Student Leader). Special Olympics Volunteer. Health Care Club. 1996.2000 STANFORD UNIVERSITY, Stanford, CA B.A.S. in Economics and Biology with Distinction. Honors: Phi Beta Kappa. Asian-American Students Association (Issues Chair). Alternative Spring Break (Course and Trip Senior Leader). Intervarsity Christian Fellowship. Experience 10/02-03/03 A.M. Pappas and Associates Intern, Venture Fund Management • Reviewed business plans for value as potential investment opportunities, evaluating in terms of technology, market opportunity, management and finance strategy • Completed competitive analyses, cash flow analyses and preliminary due diligence reports • Presented companies to investment team at weekly investment meetings • Participated in lead generation and in new company presentations 2001.2002 STANFORD UNIVERSITY, Stanford, CA Resident Assistant • Organized educational and social events. • Facilitated dorm meetings. • Mediated student conflicts. • Counseled residents on academic and personal issues. 1998.1999 VA HOSPITAL UROLOGY DEPARTMENT, Menlo Park, CA Research Assistant • Analyzed efficacy of FDG PET scans in the diagnosis and staging of advanced prostate cancer. • Compared prostate cancer grades and treatments with survival rates in patients over the age of 70. 6/99-9/99 STANFORD ECONOMICS DEPARTMENT, Stanford, CA Research Intern • Compared funding of state education programs from 1970 to 1990. • Developed mathematical algorithms to describe state programs. • Conducted primary and literature research on state education laws.
  • 6/97-9/97 M.D. ANDERSON CANCER CENTER, Houston, TX 6/96-9/96 Research Intern • Designed immunostaining procedure for detection of mutant MMAC1 gene in malignant cancers. • Analyzed efficacy of antisense TGF-α as an anti-tumorigenic agent in glioma cells. Publications Sung JC, Kabalin JN, Terris MK. Prostate cancer detection, characterization, and clinical outcomes in men aged 70 years and older referred for transrectal ultrasound and prostate biopsies. Urology. 2000 Aug 1;56(2):295-301. Sung, J., Espiritu, J.I., Segall, G.M., and Terris, M.K.: Flurodeoxyglucose Positron Emission Tomography Studies in Diagnosis and Staging of Clinically Advanced Prostate Cancer. BJU International 2003 Jul;92(1):24-7.
  • Appendix E: Curriculum Vitae of Kevin A. Schulman CURRICULUM VITAE June 2, 2003 KEVIN ALAN SCHULMAN, M.D., M.B.A. OFFICE ADDRESS Center for Clinical and Genetic Economics Duke Clinical Research Institute Duke University Medical Center P.O. Box 17969 Durham, NC 27715 TELEPHONE NUMBERS 919-668-8101 telephone 919-668-7124 fax 919-967-0110 home Email: kevin.schulman@duke.edu HOME ADDRESS 2708 Creek Run Court Chapel Hill, NC 27514 SOCIAL SECURITY NUMBER 138-44-0902 DATE OF BIRTH May 18, 1961 PLACE OF BIRTH East Orange, New Jersey MARITAL STATUS Married: 1996, Brenda Stacey Berlin Children: 1998, Jacob Berlin Schulman 2000, Eli Berlin Schulman 2002, Micah Berlin Schulman LICENSURE Pennsylvania: June 1990–December 1992 District of Columbia: October 1992–September 1999 North Carolina September 1999–present SPECIALTY CERTIFICATION 1991 Diplomate, American Board of Internal Medicine EDUCATION 1988 M.D. New York University School of Medicine; New York, New York 1988 M.B.A. The Wharton School, University of Pennsylvania, Concentration in Health Care Management; Philadelphia, Pennsylvania 1983 B.A. Dartmouth College; Hanover, New Hampshire
  • POSTGRADUATE TRAINING 1989–1991 Resident, Assistant Instructor of Medicine, Department of Medicine, Hospital of the University of Pennsylvania (Chairmen: Larry Early, M.D., John Eisenberg, M.D.) 1988–1989 Intern, Department of Medicine, Hospital of the University of Pennsylvania (Chairman: Larry Early, M.D.) PROFESSIONAL EXPERIENCE 1989–1991 Assistant Instructor of Medicine, Department of Medicine, Hospital of the University of Pennsylvania 1991–1992 Instructor of Medicine, Department of Medicine, Hospital of the University of Pennsylvania 1991–1992 Senior Fellow, Leonard Davis Institute of Health Economics, University of Pennsylvania 1992–1997 Assistant Professor of Medicine, Division of General Internal Medicine, Department of Medicine, Georgetown University Medical Center 1992–1993 Medical Director, Clinical Economics Research Unit, Division of General Internal Medicine, Department of Medicine, Georgetown University Medical Center 1992–1999 Departmental Faculty, Graduate Public Policy Institute, Georgetown University 1992–1999 Fellowship Director, Division of General Internal Medicine, Department of Medicine, Georgetown University Medical Center 1993–1999 Director, Clinical Economics Research Unit, Division of General Internal Medicine, Department of Medicine, Georgetown University Medical Center 1997–1999 Associate Professor of Medicine (tenured), Division of General Internal Medicine, Department of Medicine, Georgetown University Medical Center 1999–2001 Associate Professor of Medicine, Division of General Internal Medicine, Duke University Medical Center 1999– Director, Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center 1999– Research Associate, Health Services Research Unit, Durham Veterans Administration Medical Center, Duke University Medical Center 2000– Director, Health Sector Management Program, Fuqua School of Business, Duke University 2000– Director, Center for the Study of Health Management Program, Fuqua School of Business, Duke University 2000–2001 Adjunct Associate Professor of Business Administration, Fuqua School of Business, Duke University 2000– Senior Fellow, Duke Center for Clinical Health Policy Research, Duke University School of Medicine
  • 2000– Faculty Associate, Center for the Study of Medical Ethics and Humanities, Duke University School of Medicine 2000- Director, MDMBA Program, Duke University School of Medicine 2001 Associate Professor of Business Administration, Fuqua School of Business, Duke University (Joint Appointment) 2001- Professor of Medicine, Division of General Internal Medicine, Duke University Medical Center 2001- Professor of Business Administration, Fuqua School of Business, Duke University (Joint Appointment) 2003- Vice Chair of Business, Department of Medicine, Duke University Medical Center AWARDS, HONORS, AND MEMBERSHIPS IN HONORARY SOCIETIES 1983 Graduation cum laude, Dartmouth College 1988 Graduation with Distinction, The Wharton School, University of Pennsylvania 1990 Henry Christian Award (Top- scoring Abstract in a Subspecialty Field), National Meeting of the American Federation for Clinical Research 1990 Associates Member Prize for Outstanding Scientific Presentation, National Meeting of the Society of General Internal Medicine 1990 First Prize (Doctoral Student), Lee B. Lusted Student Prize Competition, National Meeting of the Society for Medical Decision Making 1995–1997 Faculty Development Award in Pharmacoeconomics, Pharmaceutical Research and Manufacturers of America Foundation, Inc. 1999 1999 Alice S. Hersh Young Investigator Award, Annual Meeting of the Association for Health Services Research 2001 The Dr. Herbert W. Nickens Epidemiology Award, The Association of Black Cardiologists. MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES National Societies Society for Medical Decision Making Member, 1989–present; Nominated for Trustee, 1995; Ideas Committee, 1997–present American College of Physicians Associate, 1990–1992; Member, 1992–present American Federation for Medical Research Member, 1990–present Society for General Internal Medicine
  • Member, 1990–present; Research Committee, 1993–2001; Finance Committee, 1997–2001; Glaser Award Selection Committee, 1997;Co-Chairperson, Patient-Centered Abstracts Review Committee, 2001. Association for Health Services Research Member, 1991–present; Annual Meeting Planning Committee, 1996, 1997, 2001. International Society for Pharmacoeconomics and Outcomes Research Member, 1999-present. Program Chairperson, 8th Annual Meeting, 2003. UNIVERSITY SERVICE 1990–1991 Member, Medical Board’s Committee on Quality Assurance Data and Systems, Hospital of the University of Pennsylvania 1992–1993 Member, Clinical Research Working Group, Department of Medicine, Georgetown University Medical Center 1992–1994 Member, Practice Operations Committee, Department of Medicine, Georgetown University Medical Center 1992–1997 Member, Billing Committee, Department of Medicine, Georgetown University Medical Center 1993 Member, Pharmaceutical Promotion and Costing Education Committee, Department of Medicine, Georgetown University Medical Center 1993–1994 Member, Patient Care Information System Committee, Department of Medicine, Georgetown University Medical Center 1996–1997 Member, Quality Improvement Committee, Department of Medicine, Georgetown University Medical Center 1997 Task Force Cochair, Supply Chain Management, Georgetown University Medical Center 1997 Member, Ad Hoc Committee on Public Health, Georgetown University Medical Center 1997–1998 Project Director, Medicare Coordinated Care Demonstration Project, Georgetown University Medical Center 1997–1998 Member, Thursday Group (Executive Leadership Forum), Georgetown University Medical Center 1998–1999 Member, Ad Hoc Committee on Clinical Problem-Solving and Decision-Making, Georgetown University Medical Center. 1998–1999 Member, Committee on Faculty, Georgetown University Medical Center 1999–present Health Sector Management Program Committee, Fuqua School of Business, Duke University 2000– Member, CERT Database Workgroup, Duke Clinical Research Institute 2000– Member, CERT Quality Workgroup, Duke Clinical Research Institute 2000– Member, Education Committee for the Health Policy Certificate Program, Sanford Institute of Public Policy, Duke University 2000- Member, Leadership for Executives in the Health Professions, Continuing Medical Education, Duke School of Medicine 2000- Selection Committee. Biostatistics & Bioinformatics Chairman Search Committee, Duke University Medical Center
  • 2001- Steering Committee, Center for Genome Ethics, Law and Policy. Duke Law School. Duke University. 2001- Member. Faculty Compensation Committee Academic Council. Duke University. 2002- Member. Duke Clinical Research Institute Advisory Board. Duke University Medical Center. 2003- Member. Medicine Advisory Board. Duke University Medical Center. MAJOR TEACHING AND CLINICAL RESPONSIBILITIES 1987–1993 Introduction to Health Insurance Theory for Medical Students, New York University School of Medicine, Annual Lecture 1990–1992 Lectures on Clinical Economics and Clinical Decision Making for Medical Interns, University of Pennsylvania School of Medicine 1991–1992 Teaching Instructor, Medical Clinic, Hospital of the University of Pennsylvania 1991–1992 Clinical Practice, Hospital of the University of Pennsylvania 1991–1992 Supervision of M.D./M.B.A. Student for Independent Research Project 1992 Coinstructor, Epidemiology 550: “Health Economics and Clinical Decision Making,” Master’s in Clinical Epidemiology Program Core Course, University of Pennsylvania 1992–1996 Instructor, “Health Services Research: Clinical Applications,” Graduate Public Policy Program, Georgetown University 1992–1999 Teaching Attending, Medical Clinic, Division of General Internal Medicine, Georgetown University Medical Center 1993 Guest Lecturer, Minority High School Program, New York University School of Medicine 1997–1999 Instructor, “Economic Evaluation of Medical Care,” Graduate Public Policy Program, Georgetown University 1999- Co-instructor, CRP 244: “Health Economics in Clinical Research,” Clinical Research Training Program, Duke University School of Medicine 1999– Instructor, “Health Care Policy and Systems,” Fuqua School of Business, Duke University 2000 Instructor, “Pharmaceutical Management and Policy,” Fuqua School of Business, Duke University 2000 Co-instructor, “Medical Practice and Health Systems,” Duke University School of Medicine, Second Year Medical Students. 2000 Co-instructor, “Comprehensive Introduction to Clinical Research,” Duke University Medical Center, Medical Residents 2001 Instructor, Genetics and the Biotechnology Revolution. Fuqua School of Business, Duke University 2001- Lecturer, Biotech for Business, Department of Chemistry, Duke University. 2000–2002 Preceptor, PRIME Ambulatory Care Clinic, Durham Veterans Affairs Medical Center, Duke University Medical Center STUDY SECTION
  • 1992–1993 Ad hoc National Scientific Review and Evaluation Group, National Cancer Institute 1993 Site Visitor, Cancer Center Renewal Application, National Cancer Institute 1993 Panel Member, Special Emphasis Panel for the Demonstration and Education Research Grants, National Heart, Lung, and Blood Institute March 1994 Ad hoc Member, Clinical Trials Review Committee, National Heart, Lung, and Blood Institute October 1994 Consultant, Clinical Trials Review Committee, National Heart, Lung, and Blood Institute 1994–1999 Ad Hoc Reviewer: RO-3 Application, Agency for Health Care Policy and Research 1996–1999 Ad Hoc Reviewer, Clinical Trials Review Committee, National Heart, Lung, and Blood Institute 1996 Special Emphasis Panel Member, “Referrals from Primary to Specialty Care,” Agency for Health Care Policy and Research 1997–2001 Member, Cooperative Studies Evaluation Committee (CSEC), Veterans Health Administration Cooperative Studies Program 1999, 2001 Reviewer, HCFO/Round 2 Health Tracking Proposal Review Meeting, Alpha Center and Robert Wood Johnson Foundation 1999- National Advisory Committee, Robert Wood Johnson Foundation’s Investigator Awards in Health Policy Research Program 2002 Reviewer, Special Emphasis Panel, Loan Repayment Applications, Department of Health and Human Services. 2002 Reviewer, Comprehensive International Program of Research on AIDS, National Institute of Allergy and Infectious Disease. PANELS 1992–1995 Steering Committee, Woodstock Theological Seminar: “Ethical Considerations in the Business Aspects of Health Care,” Woodstock Theological Center, Georgetown University, Washington, DC 1993 Faculty Member, Canadian Collaborative Workshop on Pharmacoeconomics, Health and Welfare Canada, Ottawa, Ontario 1993–present Panel Member, Women’s Interagency HIV Study Behavioral (Health Care Utilization) Working Group, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 1994 Working Group Member, “Secondary Prevention Strategies of CHD: Applications of ATP II Guidelines,” Division of Heart and Vascular Disease, National Heart, Lung, and Blood Institute, Bethesda, Maryland 1994 Cochairperson, National Cancer Institute Economic Conference, “The Integration of Economic Outcome Measures into NCI-Sponsored Therapeutic Trials,” Bethesda, Maryland 1994 Session Chair, Annual Meeting of the Society for Medical Decision Making, Cleveland, Ohio 1994 Cochairman, Plenary Session on Pharmacoeconomics, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Orlando, Florida
  • 1995–present Member, Clinical Economic Working Group, Cancer and Leukemia Group B (CALGB), National Cancer Institute, Bethesda, Maryland 1995 Panel Member, Workshop to Build a National Strategy for Prevention, Management and Research in Chronic Obstructive Pulmonary Disease (COPD), National Heart, Lung, and Blood Institute, Bethesda, Maryland 1995 Cochairperson, “Disease Management” Premeeting Workshop, Annual Meeting of the Society for Medical Decision Making, Tempe, Arizona December 1995 Cochairperson, DIA Disease Management Workshop, New Orleans, Louisiana 1995–1996 Working Group Member, “The Management of Patients with End-Stage Heart Failure,” Northwestern University Medical School and Duke University Medical School Symposium, Orlando, Florida (1995), Palm Beach, Florida (1996) 1995–1996 Planning Committee, Oncology Managed Care Program, Lombardi Cancer Center, and the Clinical Economics Research Unit, Georgetown University Medical Center, Bethesda, Maryland, and Arlington, Virginia (sponsored by Xerox Corporation) 1995–present Planning Committee (Chairperson, Abstract Committee [1995]; Cochairperson, Abstract Review Committee [1997]), NRSA Trainees Research Conference 1996 Participant, Mobile Breast Care Center Meeting, Department of Defense Telemedicine Test Bed, PHS Office on Women’s Health and National Cancer Institute, Bethesda, Maryland 1996 Session Chairperson, Drug Information Association Pharmacoeconomics Workshop, New Orleans, Louisiana 1996 Panel Member, “A Framework for Research and Evaluation into the Effects of Managed Care on the Pharmaceutical Marketplace,” Pharmaceutical Policy Project of the Center for Health Policy Research, George Washington University and the Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services, Arlington, Virginia 1996–1997 Chairperson, NCI/ASCO Economics Workshop, Washington, DC 1997 Education Session Chair, Outcomes Measurement, Annual Meeting of the American Society of Clinical Oncology, Denver, Colorado 1997–1998 Panel Member, “Ethical Issues in Managed Health Care Systems,” Woodstock Theological Center, Washington, DC 1997–1998 Panel Member, Ad Hoc Outcomes/Cost Effectiveness Advisory Panel, United States Pharmacopeial Convention, Inc., Rockville, Maryland 1998 Panel Member, “Barriers to Conducting Outcomes Research on Medical Imaging in the Past and How the Barriers Can be Overcome” and “Utilization of Diagnostic Tests: Assessing Appropriateness,” Methodological Issues in Diagnostic Clinical Trials: Health Services and Outcomes Research in Radiology, Office on Women’s Health of the Public Health Service, the National Cancer Institute, and the ACR Commission on Research and Technology Assessment, Bethesda, Maryland 1998 Panel Member, “Cost Management in Advanced Heart Failure,” Advanced Heart Failure Meeting, Charleston, South Carolina
  • 1998 Panel Member, “The Economics and Financing of End-of-Life Care,” Project on Death in America Meeting, Open Society Institute, Washington, DC 1998–1999 Panel Member, Total Artificial Heart Review Panel, National Heart, Lung, and Blood Institute, Bethesda, Maryland 1999 Course Coordinator: “Prospective Economic Evaluation of Clinical Trials: Methods and Analysis,” Annual Meeting of the Society for Medical Decision Making. Reno, Nevada 1999 Chairperson, “Economic Assessment in Clinical Trials: Design and Analysis” Drug Information Association, Orlando, Florida 2000 Course Coordinator: “Prospective Economic Evaluation of Clinical Trials: Methods and Analysis,” Annual Meeting of the Society for Medical Decision Making, Cincinnati, Ohio 2000 Panel Member, “Solutions for Racial and Ethnic Disparities in Health Care,” Institute for Diversity in Health Management, Advancing Health in America, Washington, DC 2000 Coordinator, “Economic Evaluations of Multicenter, Multinational Clinical Trials,” Second European Conference on the Economics of Cancer, European Organization for Research and Treatment of Cancer, Brussels, Belgium 2000 Panel Member, “Assuring Appropriate Use of Pharmaceuticals: Balancing Cost and Quality,” Prescription Drug Coverage: Rising Expenditures, Appropriate Use and Program Strategies, Agency for Healthcare Research and Quality, Washington, DC 2000 Course Coordinator: “Prospective Economic Evaluation of Clinical Trials: Methods and Analysis,” Short Course, Annual Meeting of the Society for Medical Decision Making, Cincinnati, Ohio 2000 Panel Member, “Solutions for Racial and Ethnic Disparities in Health Care”. Institute for Diversity in Health Management, Advancing Health in America, Washington, DC 2000 Panel Member, “Race, Ethics, and Health Care: Speaking Truth to Power”. Congressional Black Caucus Health Braintrust confernece. Washington, D.C. 2000 Panel Member. “The Power of Physician Payment: Designing Incentives in a New Era”. Health Care Financing and Organization and The Robert Wood Johnson Foundation. Washington, D.C. 2001 Chairperson. “Internet Health Information Programs: Overview and Market Opportunities”. Drug Information Association. Durham, North Carolina 2001 Panel Member. “The Productivity Factor: The Most Critical Variable,” ISTAHC 2001. Philadelphia, Pennsylvania 2001 Chair. “Genetics & the Biotechnology Revolution (Genome & Implications for Medicine),” Roundtable, 2001 Academy for Health Services and Health Policy Annual Meeting, Atlanta, Georgia 2001 Panel Member. “Breakfast with the Experts”, ISPOR Sixth Annual International Meeting, Arlington, Virginia. 2001 Co-Chair. “Patient Centered Abstracts”, SGIM 2001 Program Committee, SGIM 24th Annual Meeting, San Diego, California
  • 2001 Panel Member. “Specified Data Solicitation Review Panel,” The Robert Wood Johnson Foundation, Health Care Financing & Organization, Washington, D.C. 2001 Panel Member. “Ethical, Legal and Societal Issues Illustrated by Hypothetical,” Ethical, Legal, and Societal Issues in Biotechnology: A Primer for Industry Leaders, The Center for Genome Ethics, Law and Policy, Duke University, Durham, North Carolina 2001 Review Panel. “Studies of Adverse Effects of Marketed Drugs,” The Food and Drug Administration, Rockville, Maryland 2001 Panel Chair. “Genetics and the Biotechnology Revolution”. 2001 Annual Meeting of the Academy for Health Services Research and Health Policy. Atlanta, Georgia. 2001 Scientific Review Committee. Society for Medical Decision Making 23rd Annual Meeting. San Diego, California. 2002 Issues Panel Chair. “How Does Genomics Change Portfolio Management?” International Society for Pharmacoeconomics and Outcomes Research 7th Annual Meeting. Arlington, Virginia. 2002 Panel Member. Expert Meeting on Assessing the Spillover Effects of Managed Care on Medicare Fee-for-Service Expenditures. Department of Health and Human Services. Washington, D.C. 2002 Panel Member. Racial/Ethnic Bias and Health: Scientific Evidence, Methods, and Research Implications. National Institutes of Health. Vienna, Virginia 2002 Panel Member. Challenges Seniors Face in Getting the Right Drug Therapy, Idea Rich Environment Discussion. UnitedHealth Group. 2002 Co-Director. Coverage and Reimbursement (The Relationship Between Technology Approval and Reimbursement in the U.S.: Where are we? Where are we going?). Duke Clinical Research Institute. McLean, Virginia. 2003 Program Chair. International Society for Pharmacoeconomics and Outcomes Research 8th Annual Meeting. Arlington, Virginia. EDITORIAL POSITIONS 1993–2003 International Editorial Board, PharmacoEconomics 1994–1996 Working Party Member, “Methodological Guidelines for Economic Evaluations,” British Medical Journal 1995 Scientific Editor, “National Cancer Institute Conference: The Integration of Economic Outcome Measures into NCI-Sponsored Therapeutic Trials,” Journal of the National Cancer Institute Monographs, Vol 19 1996–present Editorial Board, Health Services Research 1997–present Editorial Board, American Heart Journal 1997–present Editorial Board, Disease Management 1998- Scientific Editor, Journal of the National Cancer Institute Monographs, Vol 24 1997- Scientific Advisory Board, Value in Health 2000- Editorial Board, Evidence-Based Gastroenterology 2001- Editorial Board, American Journal of Medicine 2003- Editorial Board, Cost Effectiveness and Resource Allocation.
  • STUDY CHAIRMANSHIPS AND COCHAIRMANSHIPS 1991–1996 Steering Committee Member and Lead Economic Investigator, “The Flolan International Randomized Survival Trial (FIRST)” (Protocol #P18:48), Wellcome Company and the Wellcome Foundation, Ltd 1992–1997 Lead Economic Investigator, “Tirilazad Mesylate in the Treatment of Patients with Moderate and Severe Head Injury” (Protocol #P/2700/0036), The Upjohn Company 1992–1997 Economic Investigator, “Prospective Evaluation of the Cost Effectiveness of Tirilazad Mesylate for Treatment of Subarachnoid Hemorrhage International Multi-Center Trial” (Protocol #2700-0032), The Upjohn Company 1992–1997 Economic Investigator, “Prospective Evaluation of the Cost Effectiveness of Tirilazad Mesylate for Treatment of Subarachnoid Hemorrhage North American Trial” (Protocol #2700-0029), The Upjohn Company 1993–1997 Lead Economic Investigator, “SDZ ILE 964/Prospective Evaluation Autologous Bone Marrow Transplantation with rhGM-CSF With and Without IL-3” (Protocol #02321), Novartis Pharmaceuticals Corporation 1994–1999 Lead Economic Investigator, “A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination with Didanosine (DDI) versus DDI alone in HIV-1 Infected Individuals with CD4 Counts of less than 300/mm” (Protocol #M/3331/0017), The Upjohn 1995–1997 Study Chairperson, “CALGB 9570: Development of Standard Methods for Collecting Economic Data for CALGB Trials,” Cancer and Leukemia Group B, National Cancer Institute 1996–1999 Lead Economic Investigator, “A Study of the Safety and Efficacy of Antithrombin in Patients with Heparin Resistance Undergoing Cardiopulmonary Bypass Surgery, Bayer Corporation 1997–1999 Lead Economic Investigator, “A Randomized Placebo- Controlled, Multi-Center Trial Examining the Role of Antithrombin III Treatment in the Management of Meningococcal Purpura Fulminans,” Bayer Corporation 1997–1999 Lead Economic Investigator, “Efficacy and Safety of Xemilofiban Administration to Patients Undergoing Coronary Angioplasty or Stem Placement (EXCITE)” (Protocol IG7-96-02-017), G.D. Searle & Co 1997–1999 Lead Economic Investigator, “Clinical Protocol for a Phase III International Randomized, Double-Blind Placebo-Controlled Trial Evaluating the Efficacy and Safety of Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16)” (Protocol IND #49380), G.D. Searle & Company 1998–2003 Lead Economic Investigator, “A Randomized, Double-blind, Placebo-controlled, Multicenter, Safety and Efficacy Trial of Intravenous Zoledronate (4 and 8 mg) in Prostate Cancer Patients with Metastatic Bone Lesions,” Novartis Pharmaceuticals Corporation 1998–2004 Lead Economic Investigator, “The VALIENT Trial,” Novartis Pharmaceuticals Corporation 1999–2004 Lead Economic Investigator, “The WATCH Trial” (VA Cooperative Study 442), Department of Veterans Affairs 2000-2001 Lead Economic Investigator, The Economic Evaluation of VAL-HEFT, Novartis Pharmaceuticals
  • 2001-2005 Member. OPTIMA. Trial Steering Committee, Medical Research Council, United Kingdom, Veterans Healthcare System. 2002-2003 Lead Economic Investigator, "Economic Analysis of Imitanib (Glivec/Gleevec) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia". Novartis Pharmaceuticals Corporation 2002-2006 Principal Investigator, "Economic and Quality of Life Evaluation of the ACTION (A CHF Trial Investigating Outcomes of Exercise Training) Trial". National Heart Lung and Blood Institute. 2002-2004 Lead Economic Investigator, "Quality of Life and Economic Analysis for BMS Protocol CA225006: Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Carcinoma", Bristol Myers Squibb PEER-REVIEWED GRANT SUPPORT Non-Active Source: NICHD Role: Investigator Title: The Cooperative Community-Based Prenatal Intervention Studies in Minority Population (Siva subramanian) Date of Entire Project: 9/01/92-8/31/97 Total Costs: $197,576 Source and ID No.: U.S. Army, MD17-94-J-2411 Role: Principal Investigator Title: Does Physician Description of Therapeutic Options Influence Breast Cancer Patient Treatment Choice? Date of Entire Project: 7/01/94 - 9/30/96 Total Costs: $142,873 Source: NIH/HRSA Role: Principal Investigator Title: Institutional National Research Award Date of Project: 7/01/94 - 6/30/99 Total Costs: $957,702 Source and ID No.: The Robert Wood Johnson Foundation, 24328 Role: Co-Principal Investigator Title: Selective Contracting for Tertiary Care Services by Managed Care Organizations Date of Entire Project: 7/1/94 -6/1/97 Total Costs: $71,383 Source and ID No.: U.S. Army, DAMD17-94-J-4212 Role: Investigator, Member of Executive Committee Title: Cost Effectiveness of Alternative Treatments for Local Breast Cancer in the Elderly Date of Entire Project: 8/01/94 - 8/30/97 Total Costs: $120,807 Source and ID No.: AHCPR, 5-R01-HS08395 Role: Investigator, Member of Executive Committee Title: Care, Costs and Outcomes of Local Breast Cancer in Older Women
  • Date of Entire Project: 9/30/94 - 9/29/99 Total Costs: $251,423 Source and ID No.: AHCPR, 1 R01 HS07315-01 Role: Principal Investigator Title: Race and Gender Differences in Clinical Decision-Making Date of Entire Project: 03/01/95 - 02/28/99 Total Costs: $1,073,654 Source: PhRMA Foundation Role: Principal Investigator Title: Faculty Development Award in Pharmacoeconomics Date of Entire Project: 7/01/95 - 6/30/97 Total Costs: $80,000 Source: AHCPR and HRSA Role: Principal Investigator Title: 1996 Second Annual NRSA Training Meeting Date of Entire Project: 5/1/96-4/30/97 Total Costs: $75,000 Source: National Library of Medicine Role: Investigator Title: Project Phoenix: Scrutinizing Telemedicine Test Bed Date of Entire Project: 9/30/96-1/10/99 Total Costs: $542,998 Source: HRSA/AHCPR Role: Principal Investigator Title: 1997 Third Annual NRSA Conference Date of Entire Project: 4/1/97-3/31/98 Total Costs: $100,000 Source: D.C. Government Role: Principal Investigator Title: Medicare Demonstration Project Date of Entire Project: 6/1/98-11/1/98 Total Costs: $418,900 (planning budget) Source: HRSA Role: Principal Investigator Title: Institutional National Research Service Award Date of Entire Project: 7/1/98 – 8/31/99 Total Costs: $994,373 Source: HRSA/NRSA Role: Principal Investigator Title: Institutional National Research Service Award/Supplement Award Date of Entire Project: 7/1/98 – 8/31/99 Total Costs: $827,693 Source: AHCPR Role: Principal Investigator Title: Institutional National Research Service Award Date of Entire Project: 7/1/98 – 8/31/99 Total Costs: $850,182
  • Source: EPA Role: Principal Investigator Title: Economic/Cost Analysis Associated with the Transition to CFC-Free MDIs Date of Entire Project: 9/1/98 – 1/31/99 Total Costs: $59,026 Source: NIMH Role: Investigator, Executive Committee Member Title: Mental Health Services for Woman in Public Medical Costs Date of Entire Project: 7/1/98-8/31/99 Total Costs: $300,000 Source: NCI/Foxchase Cancer Center Subcontract Role: Principal Investigator Title: Patient Decision Making in Phase I Cancer Clinical Trials Date of Entire Project: 9/29/98-9/30/01 Total Costs: $418,240 Source: Robert Wood Johnson Foundation Role: Principal Investigator Title: The Relationship Between Market Forces and the Costs, Treatments and Outcomes of Medicare Patients. Date of Entire Project: 1/1/99-6/30/01 Total Costs: $250,000 Source: NHLBI/University of Washington Subcontract Role: Principal Investigator Title: Cardiovascular Health Study Claims Data Analysis Date of Entire Project: 11/1/99 - 10/31/01 Total Costs: $83,888 Source: Agency for Health Care Research and Quality/Arizona University Subcontract Role: Investigator Title: CERT Date of Entire Project: 9/30/99 - 9/29/02 Total Costs: $864,513 Source: HRSA/AHCPR Role: Principal Investigator Title: 1998 through 2003 Annual NRSA Trainees Research Conference Date of Entire Project: 4/1/98 - 3/31/03 Total Costs: $557,699 Active Source: Durham VA/Bristol Myers Squibb Role: Principal Investigator Title: CSP 442 Date of Entire Project: 10/1/99 - 9/30/05
  • Total Costs: $200,816 Source: NHLBI Role: Principal Investigator Title: ACTION EQOL Study Date of Entire Project: 9/29/02 – 9/28/02 Total Costs: $2,602,524 LECTURES BY INVITATION September, 1987 “Introduction to Health Insurance Theory for Medical Residents,” New York University School of Medicine, New York, New York October 17, 1989 “Assessing Physicians’ Estimates of the Probability of Coronary Artery Disease,” Annual Meeting of the Society for Medical Decision Making, Minneapolis, Minnesota February, 1990 “The Cost Effectiveness of the Pharmacologic Treatment of High Blood Cholesterol,” Mid-Atlantic Regional Meeting of the Society for General Internal Medicine, Philadelphia, Pennsylvania May, 1990 “Cost-Effectiveness of Low Dose Zidovudine Therapy for Asymptomatic Patients Infected with Human Immunodeficiency Virus,” National Meeting of the American Federation for Clinical Research, Washington, DC November, 1990 “Societal Costs of Liver Transplantation: Implications for Program Management,” Annual Meeting of the Society for Medical Decision Making, Boston, Massachusetts April 6, 1991 “Cost-Effectiveness of Low Dose Zidovudine Therapy for Asymptomatic Patients Infected with Human Immunodeficiency Virus,” International Seminar Series-The Management of HIV Infection: Economic Aspects of HIV Management, The Wellcome Foundation, Lausanne, Switzerland May 9, 1991 “Cost Effectiveness as a Tool: Application to the Therapy of Hypercholesterolemia,” Endocrine Grand Rounds, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania July 2, 1991 “Technology Assessment: Clinical Economic Impact of HA-1A Monoclonal Antibody for Gram-Negative Sepsis,” Annual Meeting of the Association for Health Services Research, San Diego, California October 9, 1991 “Evaluations of the Results of Health Economics Studies: Quality of Life, Quantification of Benefits and Quality Adjusted Life Years,” Seminar on Health Economics, Presentation to the Director General of the Division of Pharmaceutical Affairs, Portuguese Health Ministry, Cascais, Portugal October 23, 1991 “Prospective Economic Assessment of Medical Technologies: Methodologic Issues in Medicare Funding of New Technologies,” Annual Meeting of the Society for Medical Decision Making, Rochester, New York November 12, 1991 “Evaluation of Cancer Diagnostic Tests: Understanding the Implications of New Technologies,” Office of Device Evaluation, Food and Drug Administration, Rockville, Maryland May 13, 1992 “Economic Assessment of Pharmaceuticals: Formulary Assessment,” Ralph D. Arnold Pharmaceutical Services Management Course, US Department of the Army, Denver, Colorado May 25, 1992 “Economic Evaluation of HA-1A Therapy,” Annual Meeting of the Society of Critical Care Medicine, San Antonio, Texas
  • June 1, 1992 “Cost Effectiveness of Cholesterol Lowering Drug Therapy,” Annual Meeting of the American Society of Hospital Pharmacists, Washington, DC September 22, 1992 “Integrating Economic Evaluations Into Phase III Clinical Trials: The Multidisciplinary Team,” Annual Seminar of the Project Management Institute, Pittsburgh, Pennsylvania September 23, 1992 “Valuing Costs and Benefits of Pharmaceuticals,” Roundtable on Cost- Effectiveness and Public Policy, Institute for Public Policy Studies, Vanderbilt University, Nashville, Tennessee October 18, 1992 “Comparing Methods to Project Cost Effectiveness Ratios from Clinical Trials,” Health Policy-Values, Outcomes and Choices, Annual Meeting of the Society for Medical Decision Making, Portland, Oregon October 19, 1992 The CDC Look back Programs for HIV Transmission: Public Transmission: Public Safety from a Negative Epidemiologic Study. March 12, 1993 “Application of Economic Analysis to Clinical Practice: The Case of HA-1A Therapy,” Second Regional Symposium of the Canadian Coordinating Office for Health Technology Assessment, Calgary, Alberta March 23-24, 1993 “Cost Effectiveness: Definitions and Overview of International Approach. Critique of Guidelines, Clinical Data, Surrogate Endpoints, Economic Assessment of Pharmaceuticals,” Meeting of the Drug Information Association, Sydney, Australia April 26, 1993 “Integrating Cost-Effectiveness Analysis into Pulmonary Rehabilitation Research,” NIH Pulmonary Rehabilitation Workshop (National Institute of Child Health & Human Development and the National Heart, Lung, and Blood Institute), Bethesda, Maryland May 1, 1993 “Economic Evaluation of Clinical Trials,” Annual Meeting of the Society for General Internal Medicine, Washington, DC June 21-22, 1993 “An International Perspective on Guidelines Development-Approaches, Challenges, and Future Directions: USA,” Canadian Collaborative Workshop on Pharmacoeconomics, Health and Welfare Canada, Sainte-Adele, Quebec December 7, 1993 “Economic Evaluation of Clinical Practice,” Annual Meeting of the American Academy of Dermatology, Washington, DC April 21, 1994 “Overview of Clinical Economics-Case Discussion: Stage II and III Breast Cancer,” National Cancer Institute Economic Conference-The Integration of Economic Outcome Measures into NCI- Sponsored Therapeutic Trials, Bethesda, Maryland April 27, 1994 “Development of the Interactive Computer Program in Clinical Economics,” Microcomputer Users Group Workshop, Annual Meeting of the Society for General Internal Medicine, Washington, DC May 9, 1994 “Economic Evaluation in Clinical Trials,” Annual Meeting of the Society for Clinical Trials, Austin, Texas July 19, 1994 “Development of Multi-Media Educational Material: A Case Study Workshop,” Annual Meeting of the American Association of Colleges of Pharmacy, Albuquerque, New Mexico September 20, 1994 “Pharmacoeconomic Claims in Drug Advertising (Rx2-87),” Annual Conference and Exhibition of the Regulatory Affairs Professionals Society, Washington, DC October 1, 1994 “Essentials of Economic Evaluation,” Economic Working Group, Cochran Colloquium, Ontario
  • October 7, 1994 “Overview of Pharmacoeconomics,” 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Orlando, Florida November 1, 1994 “New Uses of Multimedia in Computer Assisted Learning,” Association of American Medical Colleges, Boston, Massachusetts November 2, 1994 “The Role of Economic Evaluation in the Assessment of Therapeutic Efficacy for New Compounds,” Food and Drug Administration Staff College, Bethesda, Maryland November 10, 1994 “Using Economic Analysis to Determine Endpoints for Clinical Trials,” Drug Information Association Conference on Cost-Effectiveness Analysis-Measures and Methods in Clinical Trials, Orlando, Florida March 14, 1995 “Analysis of Pharmacoeconomic Data,” Drug Information Association Biostatistics Conference, Hilton Head, South Carolina April 3, 1995 “Designing Trials for Economic Evaluations,” International Symposium on Issues of Standardization in Economic Evaluations of Pharmaceuticals, Center for Pharmaceutical Outcomes Research, Chapel Hill, North Carolina May 5, 1995 “Economic Assessment of Cancer Therapies,” Annual Meeting of the Cancer and Leukemia Group B, Providence, Rhode Island June 6, 1995 “A Health Services Approach to the Evaluation of Innovative Pharmaceuticals and Biotechnology Products,” Annual Meeting of the Association for Health Services Research and the Foundation for Health Services Research, Chicago, Illinois June 29, 1995 “Prospective Economic Evaluation of Clinical Therapies,” Grand Rounds, Roswell Park Cancer Center, Buffalo, New York July 31, 1995 “Approaches for Technology Assessment in Telemedicine in the Department of Defense,” Session Provocateur, Chestertown Roundtable, Symposium of the Department of Defense Telemedicine Testbed Program, Chestertown, Maryland September 22, 1995 “Pharmacoeconomics and New Drug Evaluation,” Annual Meeting of the American College of Clinical Pharmacology, Rockville, Maryland October 10, 1995 “Designing Trials for Economic Evaluations,” Grand Rounds, Fairfax Hospital, Fairfax, Virginia October 14, 1995 “Introduction to Disease Management,” Disease Management Short Course, Annual Meeting of the Society for Medical Decision Making, Tempe, Ariz November 6-7 1995 “What Are the Issues and Problems in Defining Quality Oncology Care?,” Session Moderator, Oncology Managed Care Program, Xerox Corporation and the Lombardi Cancer Center and Clinical Economics Research Unit, Georgetown University Medical Center, Bethesda, Maryland November 10, 1995 “Designing Trials for Economic Evaluations,” Methodologies in Healthcare Outcomes in Gastroenterology: A Workshop Symposium, University of Illinois at Chicago Medical Center and the Gastroenterology Research Group, Chicago, Illinois December 1-2, 1995 “Methodological and Statistical Issues of Quality of Life and Economic Evaluation in Cancer Clinical Trials,” Session Chairperson, EORTC Symposium, Brussels, Belgium December 5, 1995 “The Rationale for Disease Management,” Drug Information Association Disease Management Workshop, New Orleans, Louisiana
  • February 27, 1996 “Clinical Economics,” Grand Rounds, Howard University Hospital, Washington, DC March 21, 1996 “Disease Management: Dissecting the Gatekeeper Model,” Agency for Health Care Policy and Research, Rockville, Maryland April 19, 1996 “Reforming the Food and Drug Administration: The Pharmaceutical Approval Process,” American Enterprise Institute for Public Policy Research, Washington, DC May 7, 1996 “HMOs’ Purchase of Tertiary Care Services in Three Markets,” Oncology Managed Care Program, Xerox Corporation and the Lombardi Cancer Center and Clinical Economics Research Unit, Georgetown University Medical Center, Arlington, Virginia July 31, 1996 “Cost-effectiveness Issues in Screening Programs,” Mobile Breast Care Center Meeting, Department of Defense Telemedicine Testbed, Office on Women’s Health, Public Health Service and the National Cancer Institute, Bethesda, Maryland August 24, 1996 “Designing Trials for Economic Evaluations,” Methodologies in Outcomes Research for Gastroenterologists Workshop, University of Illinois at Chicago Medical Center and the Gastroenterology Research Group, Seattle, Washington September 6, 1996 “Study of Bone Diseases: Economic Evaluation,” Third International Bone Disease Symposium of the International Federation of Societies on Skeletal Diseases, in conjunction with the International Society for Clinical Densitometry, Chantilly, Virginia October 24, 1996 “PBM Roundtable,” Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts November 1, 1996 “Economic Evaluation of Cancer Therapies,” Grand Rounds, Memorial Sloan Kettering Cancer Center, New York, New York November 14-15, 1996 “Design of Clinical Trials for Economic Evaluation” and “The Results of the FIRST Study Economic Evaluation,” Drug Information Association Workshop, New Orleans, Louisiana November 20, 1996 “Policy Issues in Pharmaceutical Cost-Effectiveness Research,” Discussant, American Enterprise Institute for Public Policy Research, Washington, DC March 9, 1997 “Marketing of Generic Drugs,” Annual Meeting of the Generic Pharmaceutical Industry Association, Miami, Florida April 17-19, 1997 “ACE Inhibitors for CHF: Comparative Economic Data,” Duke Clinical Research Institute, Economic and Cost Effectiveness in Evaluating the Value of Cardiovascular Therapies, St. Petersburg, Florida. May 18-19, 1997 “Outcomes Measurement” Education Session Chair, and “Health Services Research” Discussant, Annual Meeting of the American Society of Clinical Oncology, Denver, Colorado May 26, 1997 “Data Collection in Prospective Economic Studies,” Annual Meeting of the International Society of Technology Assessment in Health Care, Barcelona, Spain July 23, 1997 “Clinical Economics and Reimbursement for New Technologies,” Ministry of Health and Welfare, Tokyo, Japan July 23, 1997 “Economic Evaluation in Clinical Trials,” Keio University, Tokyo, Japan September 19, 1997 “Designing Trials for Economic Evaluation,” Speaker and Session Chair, Methodologies in Healthcare Outcomes in Gastroenterology, Philadelphia, Pennsylvania September 30, 1997 “The Relationship Between CD4 Count, Viral Burden, and Quality of Life Over Time in HIV-1 Infected Patients,” 37th Interscience
  • Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario November 6, 1997 “Introduction to Economic Assessment in Clinical Trials,” Drug Information Association Workshop, Hilton Head, South Carolina February 3, 1998 “Comparative Research on Cost Effectiveness of Alternative Disease Treatments,” New York Pharma Forum, Inc, New York, New York July 2, 1998 Speaker, “The Effect of Pharmaceutical Benefits Mangers: Is it Being Evaluated?,” Pharmaceutical Issues Seminar, Consumer Federation of America. Washington, DC September 24, 1998 “Bayesian Analysis in Laypersons’ Terms,” Session Chair, Health Economics and Outcomes Research: Making Statistics and Analysis More Relevant to Decision Makers, Medtap International and the Agency for Health Care Policy and Research, Chantilly, Virginia October 3, 1998 “What Outcomes Research Tells Us About Cost-Effectively Managing Cardiovascular Risk,” Heart to Heart Symposium, United HealthCare. Orlando, Florida October 25, 1998 “Prospective Economic Evaluation of Clinical Trials: Methods and Analysis,” Course Coordinator, Annual Meeting of the Society for Medical Decision Making, Boston, Massachusetts October 26, 1998 “The Effect of Race and Gender on Referral for Cardiac Catheterization,” Annual Meeting of the Society for Medical Decision Making, Boston, Mass October 29, 1998 “The True Costs of Pharmaceutical Therapy: Adverse Drug Reactions and Their Effect on the Health Care System,” Quality of Care, Meeting on the Needs of Diverse Populations. 13th Annual Symposium of the Center for Clinical Quality Evaluation, Arlington, Virginia November 10, 1998 “Economic Evaluation of Clinical Trials: Talking Past Customers,” Economic Assessment in Clinical Trials: Design and Analysis, Drug Information Association Workshop, New Orleans, Louisiana December 9, 1998 “The Effect of Race and Gender on Physician Recommendation for Cardiac Catheterization,” Grand Rounds, Mayo Clinic, Rochester, Minnesota March 9, 1999 “Effect of Race and Gender on Physician Recommendation for Cardiac Catheterization,” Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana May 7, 1999 “Moral Hazard Revisited: Is Health Insurance an Appropriate Financing Mechanism for Pharmaceutical Products?,” Keynote Speaker, Fifth Wintergreen Conference of the University of Maryland and the Center on Drugs and Public Policy, Wintergreen, Virginia May 14, 1999 “Academic-PRO Collaborations,” DC Campaign for Medicare Excellence, Washington, DC May 19, 1998 “Race and Gender Disparities in Health Care,” Special Guest, Congressional Black Caucus, Washington, DC May 20, 1998 “The Effect of Race and Gender on Physician Recommendation for Cardiac Catheterization,” Office of Civil Rights Managers Conference, Office of Civil Rights, Department of Health and Human Services, Washington, DC June 10, 1999 “Race and Gender Bias in Clinical Decision Making,” Women’s Health Seminar Series, Department of Health and Human Services, Washington, DC October 14, 1999 “Race as a Factor in Medical Decision-Making,” Race, Ethnicity, and Medical Care: Improving Access in a Diverse Society, The Henry J. Kaiser Family Foundation, and Washington, DC
  • October 22, 1999 “Moral Hazard Revisited: Is Health Insurance an Appropriate Financing Mechanism for Pharmaceutical Products?,” Program on Health Outcomes Seminar Series, University of North Carolina, Chapel Hill, North Carolina November 8, 1999 “Race as a Factor in Physician Decision-Making,” Eliminating Racial and Ethnic Disparities: Identifying Challenges and Building Partnerships, Mount Sinai School of Medicine and the Greater New York City Hospital Association, New York, New York November 15, 1999 “Introduction to Economic Assessment in Clinical Trails: Design and Analysis,” Drug Information Association, Orlando, Florida April 3–4, 2000 “Internet Health Information Programs: Overview and Market Opportunities,” Program Chairperson, Drug Information Association, Durham, North Carolina June 18, 2000 “The New Millennium: “The Impact of Genetics on the Structure of the Health Sector,” The Charlene Worcester Memorial Lecture, Baptist Health System. Birmingham, Alabama March 29, 2000 “Maximizing the Value of Phase III Clinical Trials”: Balancing the interest of the public in evidenced based medicine with access to new therapies and the need for return on investment by industry, Reducing Costs of Phase III Clinical Trials, Duke Clinical Research Institute, Vienna, Virginia. December 1, 2001 “Eliminating Racial Disparities in Health Care”, Racial Disparities in Health Care Outcomes: Sources, Science, and Solutions, Student National Medical Association Regional Conference. Duke University Medical Center. June 11, 2001 “Genomics and the Biotechnology Revolution” 2001 Annual Meeting of the Academy for Health Services Research and Health Policy. Atlanta, Georgia. July 20, 2001 “Race, Sex, and Clinical Decision Making,” Seminar Series on Methods in Health Disparities Research, Health Services Research, University of North Carolina, Chapel Hill, North Carolina January 22, 2002 “Eliminating Racial Disparities in Health Care,” Martin Luther King, Jr., Day Celebration. Duke University Medical Center. January 24, 2002 “The Future of the Health Care System,” Triangle Healthcare Executive Forum. Durham, North Carolina. September 24, 2002 “The Implications of Genomics for the Practice of Medicine,” The Baptist Montclair Annual Medical Staff Meeting. Birmingham, Alabama. November 1, 2002 “Results of the NEJM Survey,” Conflict of Interest Roundtable Meeting. Duke Clinical Research Institute. Tysons Corner, Virginia. July 17, 2002 “Interpreting Racial Disparities in Access to Health Care,” Ethics, Humanism and Health Care Policy Seminar of the Minority Medical Education Program. Duke University, Durham, North Carolina. February 28, 2003 “Eliminating Racial Disparities in Health Care,” Minority Health Conference, University of North Carolina. Chapel Hill, North Carolina. BIBLIOGRAPHY:
  • ORIGINAL PAPERS 1. Green J, Singer M, Wintfeld N, Schulman K, Passman L. Projecting the impact of AIDS on hospitals. Health Aff 1987; 6(3):19-31. 2. Green J, Singer M, Wintfeld N, Schulman K. AIDS in New England hospitals. N Engl J Public Policy 1987; 4(special issue):273-283. 3. Schulman KA, Kinosian B, Jacobson TA, Glick H, William MK, Koffer H et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 1990; 264(23):3025-3033. 4. Schulman KA, Glick HA, Rubin H, Eisenberg JM. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis: economic assessment of a new therapeutic agent. JAMA 1991; 266(24):3466-3471. 5. Greco PJ, Schulman KA, Lavizzo-Mourey R, Hansen-Flaschen J. The Patient Self-Determination Act and the future of advance directives. Ann Intern Med 1991; 115(8):639-643. 6. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991; 114(9):798-802. 7. Lynn LA, Schulman KA, Eisenberg JM. The pharmacoeconomics of HIV disease. Pharmacoeconomics 1992; 1(3):161-174. 8. Schulman KA, Escarce JJ, Eisenberg JM, Hershey JC, Young MJ, McCarthy DM et al. Assessing physicians' estimates of the probability of coronary artery disease: the influence of patient characteristics. Med Decis Making 1992; 12(2):109-114. 9. Seltzer E, Schulman KA, Brennan PJ, Lynn LA. Patient attitudes toward rooming with persons with HIV infection. J Fam Pract 1993; 37(6):564-568. 10. Schulman KA, McDonald RC, Lynn LA, Frank I, Christakis NA, Schwartz JS. Screening surgeons for HIV infection: assessment of a potential public health program. Infect Control Hosp Epidemiol 1994; 15(3):147-155. 11. Schulman K, Sulmasy DP, Roney D. Ethics, economics, and the publication policies of major medical journals. JAMA 1994; 272(2):154-156. 12. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke 1994; 25(9):1721-1725. 13. Roulidis ZC, Schulman KA. Physician communication in managed care organizations: opinions of primary care physicians. J Fam Pract 1994; 39(5):446-451. 14. Schulman KA, Glick HA. Economic evaluation of high-dose chemotherapy and bone marrow transplantation for patients with breast cancer of stage II or IIIA with more than 10 positive lymph nodes at surgical excision. J Natl Cancer Inst Monogr 1995;(19):45-50. 15. Lee JH, Glick HA, Kinosian B, Schulman KA. An interactive computer system for formulary management using cost-effectiveness analysis. MD Comput 1995; 12(1):59-65. 16. Morris CB, Schulman KA. The emerging role of the Food and Drug Administration in pharmacoeconomic evaluation during the drug development process. Drug Inf J 1995; 29:1105-1111. 17. Schulman KA, Yabroff KR, Glick H. A health services approach for the evaluation of innovative pharmaceutical and biotechnology products. Drug Inf J 1995; 29:1405-1414. 18. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA 1996; 275(24):1885-1892. 19. Hirsh JA, Langlotz CP, Lee J, Tanio CP, Grossman RI, Schulman KA. Clinical assessment of MR of the brain in nonsurgical patients. Am J Neuroradiol 1996; 17(7):1245-1253. 20. Schulman KA, Glick H, Buxton M, Sculpher M, Backhouse M, Bell L et al. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. Control Clin Trials 1996; 17(4):304-315. 21. Knollmann BC, Corson AP, Twigg HL, Schulman KA. Assessment of joint review of radiologic studies by a primary care physician and a radiologist. J Gen Intern Med 1996; 11(10):608-612.
  • 22. Schulman KA, Buxton M, Glick H, Sculpher M, Guzman G, Kong J et al. Results of the economic evaluation of the FIRST study: a multinational prospective economic evaluation. Flolan International Randomized Survival Trial. Int J Technol Assess Health Care 1996; 12(4):698-713. 23. DeChant HK, Tohme WG, Mun SK, Hayes WS, Schulman KA. Health systems evaluation of telemedicine: a staged approach. Telemed J 1996; 2(4):303-312. 24. Mauskopf J, Schulman K, Bell L, Glick H. A strategy for collecting pharmacoeconomic data during phase II/III clinical trials. Pharmacoeconomics 1996; 9(3):264-277. 25. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313(7052):275-283. 26. Schulman KA, Rubenstein LE, Seils DM, Harris M, Hadley J, Escarce JJ. Quality assessment in contracting for tertiary care services by HMOs: a case study of three markets. Jt Comm J Qual Improv 1997; 23(2):117-127. 27. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997; 6(3):243-252. 28. Mitchell JM, Meehan KR, Kong J, Schulman KA. Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. J Clin Oncol 1997; 15(7):2644-2651. 29. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Development and validation of a rhino conjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. J Allergy Clin Immunol 1997; 100(1):16-22. 30. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134(1):44-54. 31. Roulidis ZC, DeChant HK, Schulman KA. Resource utilization control processes as indicators of quality in managed care organizations: a proposal. Am J Med 1997; 103(2):146-151. 32. Winchester JF, Tohme WG, Schulman KA, Collmann J, Johnson A, Meissner MC et al. Hemodialysis patient management by telemedicine: design and implementation. ASAIO J 1997; 43(5):M763-M766. 33. Tohme WG, Winchester JF, Collmann J, Johnson AE, Khanafer N, Meissner MC et al. Remote management of haemodialysis patients: design and implementation of a telemedicine network. Minim Invasive Ther Allied Technol 1997; 5/6:421-428. 34. Gaskin DJ, Kong J, Meropol NJ, Yabroff KR, Weaver C, Schulman KA. Treatment choices by seriously ill patients: the Health Stock Risk Adjustment model. Med Decis Making 1998; 18(1):84-94. 35. Glick HA, Polsky D, Willke RJ, Alves WM, Kassell N, Schulman K. Comparison of the use of medical resources and outcomes in the treatment of aneurysmal subarachnoid hemorrhage between Canada and the United States. Stroke 1998; 29(2):351-358. 36. Glick H, Willke R, Polsky D, Llana T, Alves WM, Kassell N et al. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage: economic evaluation of a phase III clinical trial in Europe and Australia. Int J Technol Assess Health Care 1998; 14(1):145-160. 37. Sulmasy DP, Linas BP, Gold KF, Schulman KA. Physician resource use and willingness to participate in assisted suicide. Arch Intern Med 1998; 158(9):974-978. 38. Schulman KA, Dorsainvil D, Yabroff KR, DiCesare J, Felser J, Eisenberg JM et al. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21(6):607-614. 39. Neymark N, Kiebert W, Torfs K, Davies L, Fayers P, Hillner B et al. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. Eur J Cancer 1998; 34(9):1317-1333. 40. Schulman K, Burke J, Drummond M, Davies L, Carlsson P, Gruger J et al. Resource costing for multinational neurologic clinical trials: methods and results. Health Econ 1998; 7(7):629-638. 41. Rathore SS, Mehta SS, Boyko WL, Jr., Schulman KA. Prescription medication use in older Americans: a national report card on prescribing. Fam Med 1998; 30(10):733-739. 42. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7(6):481-493.
  • 43. Schulman KA, Berlin JA, Harless W, Kerner JF, Sistrunk S, Gersh BJ et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 1999; 340(8):618-626. 44. Schulman KA, Yabroff KR, Kong J, Gold KF, Rubenstein LE, Epstein AJ et al. A claims data approach to defining an episode of care. Health Serv Res 1999; 34(2):603-621. 45. De Jonge KE, Sulmasy DP, Gold KG, Epstein A, Harper MG, Eisenberg JM et al. The timing of do- not-resuscitate orders and hospital costs. J Gen Intern Med 1999; 14(3):190-192. 46. Boyko WL, Jr., Glick HA, Schulman KA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data. Am Heart J 1999; 137(5):S115-S119. 47. Schulman KA, Birch R, Zhen B, Pania N, Weaver CH. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999; 17(4):1227-1233. 48. Berger AK, Schulman KA, Gersh BJ, Pirzada S, Breall JA, Johnson AE et al. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. JAMA 1999; 282(4):341-348. 49. Schulman KA, Abernethy DR, Rathore SS, Woosley RL. Regulating manufacturer-affiliated communication in the information age. Clin Pharmacol Ther 1999; 65(6):593-597. 50. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Item responsiveness of a rhinitis and asthma symptom score during a pollen season. J Asthma 1999; 36(5):459-465. 51. Weinfurt KP, Willke R, Glick HA, Schulman KA. Towards a composite scoring solution for the Neurobehavioral Functioning Inventory. Qual Life Res 1999; 8(1-2):17-24. 52. Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). Am J Hypertens 1999; 12(4 Pt 1):333-340. 53. Mehta SS, Suzuki S, Glick HA, Schulman KA. Determining an episode of care using claims data: diabetic foot ulcer. Diabetes Care 1999; 22(7):1110-1115. 54. Glick HA, Polsky D, Willke RJ, Schulman KA. A comparison of preference assessment instruments used in a clinical trial: responses to the visual analog scale from the EuroQol EQ-5D and the Health Utilities Index. Med Decis Making 1999; 19(3):265-275. 55. Freeman VG, Rathore SS, Weinfurt KP, Schulman KA, Sulmasy DP. Lying for patients: physician deception of third-party payers. Arch Intern Med 1999; 159(19):2263-2270. 56. Schulman KA, Mehta SS, Gersh BJ, Schneider EC, Wilcox CS. Study of Hypertensive Prescribing Practices (SHyPP): a national survey of primary care physicians. J Clin Hypertens 1999; 1(2):106-114. 57. Bentham WD, Cai L, Schulman KA. Characteristics of hospitalizations of HIV-infected patients: an analysis of data from the 1994 Healthcare Cost and Utilization Project. JAIDS 1999; 22(5):503-508. 58. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000; 18(1):43-53. 59. Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ et al. Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 2000; 18(2):421-428. 60. Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly : prevalence and outcomes. Circulation 2000; 101(9):969-974. 61. Weinfurt KP, Willke RJ, Glick HA, Freimuth WW, Schulman KA. Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Med Care 2000; 38(4):404-410. 62. Rathore SS, Lenert LA, Weinfurt KP, Tinoco A, Taleghani CK, Harless W et al. The effects of patient sex and race on medical students' ratings of quality of life. Am J Med 2000; 108(7):561-566. 63. Every NR, Maynard C, Schulman K, Ritchie JL. The association between institutional primary angioplasty procedure volume and outcome in elderly Americans. J Invasive Cardiol 2000; 12(6):303-308.
  • 64. Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer 2000; 89(3):561-573. 65. Rathore SS, McGreevey JD, Schulman KA, Atkins D. Mandated coverage for cancer-screening services (2). Whose guidelines do states follow? Am J Prev Med 2000; 19(2):71-78. 66. Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 2000; 64(4):251-256. 67. Rathore SS, Berger AK, Weinfurt KP, Feinleib M, Oetgen WJ, Gersh BJ et al. Race, sex, poverty, and the medical treatment of acute myocardial infarction in the elderly. Circulation 2000; 102(6):642-648. 68. Sheifer SE, Rathore SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Breall JA et al. Time to presentation with acute myocardial infarction in the elderly : associations with race, sex, and socioeconomic characteristics. Circulation 2000; 102(14):1651-1656. 69. Backhouse ME, Gnanasakthy A, Schulman KA, Akehurst R, Glick H. The development of standard economic datasets for use in the economic evaluation of medicines. Drug Inf J 2000; 34:1273-1291. 70. Kim J, Morris CB, Schulman KA. The role of the Food and Drug Administration in pharmacoeconomic evaluation during the drug development process. Drug Inf J 2000; 34(4):1207-1213. 71. Meehan KR, Areman EM, Ericson SG, Matias C, Seifeldin R, Schulman K. Mobilization, collection, and processing of autologous peripheral blood stem cells: development of a clinical process with associated costs. J Hematother Stem Cell Res 2000; 9(5):767-771. 72. Rathore SS, Gersh BJ, Berger PB, Weinfurt KP, Oetgen WJ, Schulman KA et al. Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes. Am Heart J 2001; 141(1):47-54. 73. Berger AK, Breall JA, Gersh BJ, Johnson AE, Oetgen WJ, Marciniak TA et al. Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (The Cooperative Cardiovascular Project). Am J Cardiol 2001; 87(3):272-277. 74. Polsky D, Willke RJ, Scott K, Schulman KA, Glick HA. A comparison of scoring weights for the EuroQol((c)) derived from patients and the general public. Health Econ 2001; 10(1):27-37. 75. Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon AJ. Treatment of patients with myocardial infarction who present with a paced rhythm. Ann Intern Med 2001; 134(8):644-651. 76. Polsky D, Weinfurt KP, Kaplan B, Kim J, Fastenau J, Schulman KA. An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. Nephrol Dial Transplant 2001; 16(5):1028-1033. 77. Weaver C, Schulman K, Buckner C. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant 2001; 27(Suppl 2):S23-S29. 78. Rathore SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Schulman KA, Solomon AJ. The role of reperfusion therapy in paced patients with acute myocardial infarction. Am Heart J 2001; 142(3):516-519. 79. DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001; 9(7):545-551. 80. Schulman KA, Yabroff KR, Kong J, Gold KF, Rubenstein LE, Epstein AJ et al. A claims data approach to defining an episode of care. Pharmacoepidemiol Drug Saf 2001; 10(5):417-427. 81. Weaver CH, Buckner CD, Curtis LH, Bajwa K, Weinfurt KP, Wilson-Relyea BJ et al. Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. Bone Marrow Transplant 2002; 29(2):159-164. 82. Weinfurt KP, Trucco SM, Willke RJ, Schulman KA. Measuring agreement between patient and proxy responses to multidimensional health-related quality-of-life measures in clinical trials: an application of psychometric profile analysis. J Clin Epidemiol 2002; 55(6):608-618. 83. Gaskin D, Escarce JJ, Schulman K, Hadley J. The determinants of HMOs’ contracting with hospitals for bypass surgery. Health Serv Res. 2002;37(4):963-984.
  • 84. Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med. 2002;347(17):1335-1341. 85. Polsky D, Keating NL, Weeks JC, Schulman KA. Patient choice of breast cancer treatment: impact on health state preferences. Med Care. 2002;40(11):1068-1079. 86. Onken JE, Friedman JY, Subramanian S, Weinfurt KP, Reed SD, Malenbaum JH et al. Treatment patterns and costs associated with sessile colorectal lesions. Am J Gastroenterol. 2002;97(11):2896-2901. 87. Castel LD, Timbie JW, Sendersky V, Curtis LH, Feather KA, Schulman KA. Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care. BMC Health Serv Res. 2003;3(1):1. 88. Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114(2):135-141. 89. Law AW, Reed SD, Sundy JS, Schulman KA. Direct costs of allergic rhinitis in the united states: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol. 2003;111(2):296-300. 90. Schulman KA, Stadtmauer EA, Reed SD, Glick HA, Goldstein LJ, Pines JM et al. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer. Bone Marrow Transplant. 2003;31(3):205-210. 91. Polsky D, Mandelblatt JS, Weeks JC, Venditti L, Hwang YT, Glick HA et al. Economic evaluation of breast cancer treatment: considering the value of patient choice. J Clin Oncol. 2003;21(6):1139-1146. Original articles in press: 1. Reed SD, Friedman JY, Gnanasakthy A, Schulman KA. Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. Int J Technol Assess Health Care. In press. 2. Weinfurt KP, Castel LD, Sulmasy DP, Balshem A, Benson AB III, Burnett CB et al. The relationship between patient characteristics and expectations of benefit from phase I clinical trials. Cancer. In press. 3. Weinfurt KP, Sulmasy DP, Schulman KA, Meropol NJ. Patient expectations regarding benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theor Med Bioeth. In press. 4. Sloan FA, Trogdon JG, Curtis LH, Schulman KA. Does the ownership of the admitting hospital make a difference? Outcomes and process of care of Medicare beneficiaries admitted with acute myocardial infarction. Med Care. In press. 5. Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB III, Castel LD, et al. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician- patient communication. J Clin Oncol. In press. 6. Sloan FA, Trogdon JG, Curtis LH, Schulman KA. The impact of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction. J Am Geriatr Soc. In press. Reviews and Editorials: 1. Schulman KA, Lynn LA. A primer on cost-effectiveness studies. Drug Benefit Topics 1990; 2:13-17. 2. Schulman KA. Basics of health insurance reimbursement. Hosp Physician 1990; 26:23-27. 3. Glick H, Kinosian B, Schulman K. Decision analytic modeling: some uses in the evaluation of new pharmaceuticals. Drug Inf J 1994; 28:691-707.
  • 4. Schulman KA, Glick HA, Yabroff KR, Eisenberg JM. Introduction to clinical economics: assessment of cancer therapies. J Natl Cancer Inst Monogr 1995;(19):1-9. 5. Schulman KA, Rubenstein LE, Chesley FD, Eisenberg JM. The roles of race and socioeconomic factors in health services research. Health Serv Res 1995; 30(1 Pt 2):179-195. 6. Schulman KA, Yabroff KR. Measuring the cost-effectiveness of cancer care. Oncology 1995; 9(6):523-533. 7. Yabroff KR, Linas BP, Schulman K. Evaluation of quality of life for diverse patient populations. Breast Cancer Res Treat 1996; 40(1):87-104. 8. Schulman KA, Rubenstein LE, Glick HA, Eisenberg JM. Relationships between sponsors and investigators in pharmacoeconomic and clinical research. Pharmacoeconomics 1995; 7(3):206-220. 9. Schulman KA. Economics of bone marrow transplantation. J Clin Oncol 1996; 14(5):1409-1410. 10. Schulman KA, Rubenstein LE, Abernethy DR, Seils DM, Sulmasy DP. The effect of pharmaceutical benefits managers: is it being evaluated? Ann Intern Med 1996; 124(10):906-913. 11. Schulman KA, Llana T, Yabroff KR. Economic assessment within the clinical development program. Med Care 1996; 34(12 Suppl):DS89-DS95. 12. Schulman KA. Understanding the economic savings and costs of periodic mammographic screening in the workplace. Oncology 1996; 10(3):285-284. 13. Tom E, Schulman KA. Mathematical models in decision analysis. Infect Control Hosp Epidemiol 1997; 18(1):65-73. 14. Schulman KA, Linas BP. Pharmacoeconomics: state of the art in 1997. Annu Rev Public Health 1997; 18:529-548. 15. Schulman KA, Johnson AE, Rathore SS. The use of satisfaction measures in oncology. ASCO Education Book 1997; Spring:337-341. 16. Schulman KA, Boyko WL, Jr. Evaluating cancer costs in NCI trials. Cancer Treat Res 1998; 97:37-52. 17. Schulman KA, Mark DB, Califf RM. Outcomes and costs within a disease management program for advanced congestive heart failure. Am Heart J 1998; 135(6 Pt 2 Su):S285-S292. 18. Schulman KA. Beyond survival: economic analyses of chemotherapy in advanced, inoperable, non small cell lung cancer. Oncology 2000; 12:219-223. 19. Schulman KA, Ohishi A, Park J, Glick HA, Eisenberg JM. Clinical economics in clinical trials: the measurement of cost and outcomes in the assessment of clinical services through clinical trials. Keio J Med 1999; 48(1):1-11. 20. Sheifer SE, Schulman KA. Racial differences in the use of invasive cardiac procedures: a continuous quality improvement approach. Am Heart J 1999; 138(3 Pt 1):396-399. 21. Winchester JF, Levine B, Collmann J, Schulman KA, Turner JW, Rathore S et al. Telemedicine: future promise for dialysis management. Semin Dial 1999; 12(Suppl 1):S-101-S-103. 22. Sheifer SE, Escarce JJ, Schulman KA. Race and sex differences in the management of coronary artery disease. Am Heart J 2000; 139(5):848-857. 23. Schulman KA, Kim JJ. Medical errors: how the US government is addressing the problem. Curr Control Trials Cardiovasc Med 2000; 1(1):35-37. 24. Einbinder LC, Schulman KA. The effect of race on the referral process for invasive cardiac procedures. Med Care Res Rev 2000; 57 Suppl 1:162-180. 25. Seils DM, Friedman JY, Schulman KA. Sex differences in the referral process for invasive cardiac procedures. J Am Med Womens Assoc 2001; 56(4):151-154. 26. Schulman KA. Understanding attitudes toward clinical research. J Ambul Care Manage. 2003;26(1):88-90. 27. Schulman KA, Seils DM. Outcomes research in oncology: improving patients’ experiences with cancer treatment. Clin Ther. 2003;25(2):665-670.
  • MONOGRAPHS 1. Brown M, Glick HA, Harrell F, Herndon J, McCabe M, Moinpour C et al. Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology economics workbook. J Natl Cancer Inst Monogr 1998;(24):1-28. BOOK REVIEWS AND OTHER 1. Merkel PA, Schulman KA. Ranitidine to prevent recurrence of duodenal ulcer. N Engl J Med 1989; 321(12):835-836. 2. Schulman K. Screening for colorectal cancer. Ann Intern Med 1990; 113(4):333-334. 3. Schulman KA. Book Review. The health care cost containment crisis: fears, opinions, an facts. N Engl J Med 1990; 322:139. 4. Hennessy S, Fogarty PM, Schulman KA, Mignott H. Gastric obstruction with extended- release tablets. DICP 1991; 25(6):678-679. 5. Schulman KA. Integrating pharmacoeconomic evaluations into phase III clinical trials: the multidisciplinary team. Proceedings of the 1992 Project Management Institute Annual Meeting: Managing Our Future. Drexel Hill: Project Management Institute, 1992: 191-195. 6. Schulman KA. Book Review. Health insurance and public policy. Governance 1994; 7:107-108. 7. Colson RS, Rubenstein LE, Hadley J, Schulman K. Evaluation of Payment for Trauma Physicians: Report to the Physician Payment Review Commission. Washington, DC: Georgetown University Medical Center; 1994. 8. Schulman K. Cost-effective analyses. N Engl J Med 1995; 332(2):124. 9. Schulman KA. The politics of health care reform: lessons from the past, prospects for the future; Edited by James A. Morone and Gary S. Belkin. N Engl J Med 1995; 332(3):195. 10. Schulman KA. Coronary angioplasty had a lower 5-year cost than bypass surgery only in patients with 2-vessel coronary disease. ACP J Club 1997; 127:25. 11. Schulman KA, Berlin JA, Escarce JJ. Race, sex, and physicians' referrals for cardiac catheterization. N Engl J Med 1999; 341(4):285-287. 12. Weinfurt KP, Rathore SS, Schulman KA. ACI-TIPI clinical trial: acute cardiac ischemia time-insensitive predictive instrument. Ann Intern Med 1999; 131(6):476-477. 13. Cai L, Weinfurt KP. An SAS/IML module for Johnson-Neyman procedure. Appl Psych Meas 1999; 23(4):308. 14. Berger AK, Schulman KA, Gersh BJ. Primary angioplasty vs thrombolysis in the elderly. JAMA 2000; 283:601. 15. Sulmasy DP, Freeman VG, Schulman KA. The factuality of health records. Arch Intern Med 2000; 160(14):2224-2225. 16. Gonzales J, Kaufman J, Schulman K. Pharmacy Benefits Managers’ Drug Formulary Recommendations: Implications for Older Americans. 2000-20. Washington, DC, Public Policy Institute, Association of American Retired Persons; 2000. 17. Schulman KA, Seils DM, Califf RM. Clinical-trial agreements between medical schools and industry. N Engl J Med. 2003;348(5):476-478. NON-REFEREED 1. Drummond M, Schulman K, Weinstein M, Jonsson B. From efficacy to cost-effectiveness. OHE Briefing 1998; 37:1-12.
  • BOOK CHAPTERS 1. Schulman KA. The use of evaluation in pharmaceutical reimbursement decisions in the United States. In: Schubert F, editor. Proceedings: The Canadian Collaborative Workshop on Pharmacoeconomics. Princeton, NJ: Excerpta Medica; 1993: 19-23. 2. Eisenberg JM, Schulman KA, Glick H, Koffer H. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom B, editor. Pharmacoepidemiology. New York: John Wiley & Sons; 1994: 462-493. 3. Schulman KA. Pharmacoeconomics and clinical practice: a physician's view. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of Pharmacoeconomics. Cincinnati, Ohio: Harvey Whitney Books; 1996: 252-270. 4. Schulman KA, Glick HA, Detsky AS. Introduction to decision analysis. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, editors. Evidence Based Cardiology. London: BMJ Books; 1998: 92-111. 5. Schulman KA, Boyko WL. Evaluating cancer costs in NCI trials. In: Bennett CL, Pajeau TS, editors. Cancer Policy: Research and Methods. Boston: Kluwer Academic Publishers; 1998. 6. Schulman KA. Costs and outcomes. In: Stein JH, Eisenberg JM, editors. Internal Medicine. St. Louis: Mosby; 1998. 7. Gonzales J, Schulman K. Pharmacoeconomics. In: Richards SS, Musser WS, Gershon S, editors. Maintenance Pharmacotherapies for Neuropsychiatric Disorders. Philadelphia, Penn: Brunner/Mazel; 1999: 29-54. 8. Schulman KA, Glick H, Polsky D, Eisenberg JM. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom BL, editor. Pharmacoepidemiology. 2nd ed. Chichester, UK: John Wiley & Sons; 2000: 573-601. 9. Schulman KA, Glick HA, Polsky D, John KR, Eisenberg JM. Pharmacoeconomics. In: van Boxtel CJ, Santoso B, Edwards IR, editors. Drug Benefits and Risks: International Textbook on Clinical Pharmacology. Chichester, UK: John Wiley & Sons; 2001: 37-53. 10. Glick HA, Polsky DP, Schulman KA. Trial-based economic evaluations: an overview of design and analysis. In: Drummond M, McGuire A, editors. Economic Evaluation in Health Care: Merging Theory With Practice. Oxford, UK: Oxford University Press; 2001: 113-140. 11. Schulman KA, Seils DM. Clinical economics. In: Max MB, Lynn J, eds. Interactive Textbook on Clinical Symptom Research [online book]. Bethesda, Md: National Institute of Dental and Craniofacial Research; 2002. Available at http://www.symptomresearch.org/. 12. Schulman KA, Glick HA, Detsky AS. Introduction to decision analysis. In: Yusuf S et al, editors. Evidence Based Cardiology. 2nd ed. London: BMJ Books; 2003: 56-70. Book chapters in press: 1. Schulman KA. Pharmacoeconomics and clinical practice: a physician's view. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of Pharmacoeconomics. 2nd ed. Cincinnati, Ohio: Harvey Whitney Books; in press. 2. Kaul P, Schulman KA. Costs of care and cost-effectiveness analysis: primary prevention of coronary artery disease. In: Weintraub WS, editor. Cardiovascular Health Care Economics. Totowa, NJ: The Humana Press, Inc; in press. COMPUTER PROGRAMS 1. Schulman KA, Drummond M, Bootman JL, Rice D, Torrance G, Steinberg E, Sloan F, eds. Health Economics [computer program]. Version 1. East Hanover, NJ: Sandoz Pharmaceuticals Corporation; 1996.
  • PAPERS SUBMITTED 1. Liao L, Whellan DJ, Tabuchi K, Schulman KA. Differences in care-seeking behavior for acute chest pain in the United States and Japan. Submitted to Am Heart J. 2. Gaskin DJ, Weinfurt KP, Castel LD, Balshem A, Benson A, Burnett CB et al. An exploration of the Health Stock Risk Adjustment Model in advanced cancer patients. Submitted to Med Decis Making. 3. Rao SV, Schulman KA, Chen AY, Stafford JA, Diehr P, Jollis JG. Illness severity, medications, prior expenditures, and subsequent hospitalizations of Medicare beneficiaries who enrolled in Medicare managed care plans. Submitted to N Engl J Med. 4. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA. Effects of skeletal-related events on the health-related quality of life of patients with metastatic prostate cancer. Submitted to J Natl Cancer Inst. 5. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life for breast cancer patients receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Submitted to Med Care. 6. Castel LD, Weinfurt KP, Reed SD, Li Y, Benson AB III, Burnett CB et al. Use of the EuroQol visual analog scale in assessing longitudinal changes in the quality of life of cancer patients: a comparison of subscales of the Medical Outcomes Survey Short Form-12. Submitted to Qual Life Res. 7. Friedman JY, Reed SD, Weinfurt KP, Kahler KH, Walter EB, Schulman KA. Parents' preferences for children with atopic dermatitis. Submitted to Arch Dermatol. 8. Shah BR, Reed SD, Francis J, Ridley DB, Schulman KA. The cost of inefficiency: hospital overhead costs in the United States, 1985-1997. Submitted to J Health Care Finance. 9. Curtis LH, Ostbye T, Sendersky V, et al. Inappropriate prescribing for elderly Americans in a large outpatient population. Submitted to Arch Intern Med. 10. Polsky D, Glick HA, Suzuki S, Schulman KA. Estimating medical costs from censored data when censoring is not completely at random. Submitted to Health Econ. 11. Harpole LH, Oddone EZ, Stechuchak KM, Schulman KA. Technology in primary care practices and the impact of managed care. Submitted to Arch Intern Med. 12. Torti FM Jr, Gwyther LP, Reed SD, Friedman JY, Schulman KA. A multinational analysis of recent trends and reports in dementia caregiver burden. Submitted to Alzheimer Dis Assoc Disord. 13. Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Cohn JN, et al. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT. Submitted to Am Heart J. 14. Curtis LH, Law AW, Anstrom KJ, Schulman KA. The insurance effect on prescription drug expenditures among the elderly. Submitted to Med Care. 15. Rao SV, Schulman KA, Curtis LH, Gersh BJ, Jollis JG. Socioeconomic status, process of care, and outcome after acute myocardial infarction. Submitted to Arch Intern Med. 16. Bundorf MK, Escarce JJ, Stafford JA, Gaskin D, Jollis JG, Schulman K. Impact of managed care on the treatment, costs, and outcomes of fee-for-service Medicare patients with acute myocardial infarction. Submitted to Health Serv Res. 17. Curtis LH, Seils DM, Schulman KA. The cost of regulation in health services delivery: insights from disruptive innovation theory. Submitted to Milbank Q. ABSTRACTS (Selected 108) 1. Schulman KA, Bootman JL, Brook RA, Piech CT, Spinelli T, Begany GM, Berlinski GA, Ayers WR. An interactive computer program to teach clinical economics. Presented at: American Association of Colleges of Pharmacy Annual Meeting; July 1994; Albuquerque, NM. 2. Gonzales J, McNeil M, Schulman KA, Epstein S, Goldstein D, Goldberg R. Assessing patient preferences for depression health states. Presented at: Association for Health Services Research Annual Meeting; June 12-14, 1994; San Diego, Calif.
  • 3. Gonzales J, McNeil M, Schulman K, Epstein S, Goldstein D, Goldberg R. Assessing patient preferences for depression health states. Presented at: Annual Meeting of the Scuola Grande di San Giovanni Evangelista; 1994; Venice, Italy. 4. Gonzales J, McNeil M, Schulman K, Epstein SA, Goldstein D, Goldberg R. Assessing preferences for depression health states in medically ill outpatients. Presented at: Academy of Psychosomatic Medicine Annual Meeting; October 1994; New Orleans, La. 5. Wasserfallen JB, Milzman D, Wethington S, Wilson B, Schulman KA. Asthma symptoms, treatment and cost after an emergency room visit (ERV). J Allergy Clin Immunol 1995;95:227. 6. Glick H, Schulman KA, Buxton M, Sculpher M, Guzman G, Kong J, Eisenberg JM, FIRST Investigators. Relationship of functional status and patient preferences in heart failure patients. Presented at: Annual Meeting of the International Society of Technology Assessment in Health Care; 1995. 7. Gold KF, Weeks J, Lee P, Guzman G, Schulman K. Disease-specific health states: determining criteria for optimal instrument construction in cost-utility analysis. Med Decis Making 1995;15:432. 8. Yabroff KR, Rubenstein LE, Gold KF, Lerman C, Weaver C, Meropol NJ, Schulman K. Information framing in physician description of treatment options for cancer patients. Med Decis Making 1995;15:432. 9. Yabroff KR, Rubenstein LE, Lerman C, Boekeloo B, Schulman KA. Physician communication: What information is being conveyed to cancer patients? J Gen Intern Med 1996;11(Suppl):67. 10. DeChant HK, Khera SY, Gold KF, Schulman KA. Magnetic resonance imaging of the brain affects clinicians’ diagnostic probability estimates, but not patient management. J Gen Intern Med 1996;11(Suppl):68. 11. Yabroff KR, Boekeloo B, Seils DM, Schulman KA. Measuring information framing in a clinical setting: a novel approach to instrument development. Presented at: Psychosocial and Behavioral Factors in Women’s Health: Research, Prevention, Treatment, and Service Delivery in Clinical and Community Settings, American Psychological Association; 1996. 12. Schulman KA. Developing information for health-care decision-makers: idea to product-the process. Serono Symposia USA; 1996. 13. Gold KF, Linas BP, Schulman KA. Are group and individual scenarios measuring different things? A psychometric evaluation of medical treatment scenarios. Med Decis Making 1996;16:458. 14. Tinoco A, Lenert L, Escarce J, Harless W, Schulman K. Impact of patient race and gender on perceived utility for health states. Med Decis Making 1996;16:466. 15. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Development and validation of a rhinitis and asthma symptom score for use as an outcome measure in clinical trails. Am J Respir Crit Care Med 1996;153:A97. 16. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Comparison of responsiveness of a rhinitis and asthma symptoms score with quality of life instruments an outcome measure. Am J Respir Critical Care Med 1996;153:A97. 17. Weinfurt KP, Willke R, Glick H, Freimuth WW, Schulman KA. The relationship between CD4 count, viral burden, and quality of life over time in HIV-1 infected patients. Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997. 18. Boyko WL, Rathore SS, Johnson AE, Kong JA, Dicesare J, Schulman KA. Sociodemographic factors and payer-type as predictors for cardiac transplantation in the United States. Presented at: New Dimensions in Transplantation; 1997. 19. Boyko WL, Rathore SS, Johnson AE, Kong JA, Schulman KA. Sociodemographic factors and access to cardiac transplantation: An analysis of 1991 and 1994 state discharge data. Med Decis Making 1997;4:518. 20. Boyko WL, Glick HA, Tracy C, Solomon A, Schulman KA. Prophylactic implantable cardioverter defibrillator implanted on an outpatient basis: a decision analytic model and the impact on medicare. Med Decis Making 1997;4:538. 21. Boyko WL, Rathore SS, Johnson AE, Kong JA, Schulman KA. Sociodemographic factors and access to liver transplantation: An analysis of 1991 and 1994 state discharge data. Med Decis Making 1997;4:529.
  • 22. Tabuchi K, Rathore SS, Garber AM, Eisenberg JM, Schulman KA. Care seeking behavior for acute chest pain in the United States and Japan. Med Decis Making 1997;4:540. 23. Glick H, Polsky D, Willke RJ, Schulman KA. Patient preferences after aneurysmal subarachnoid: A hemorrhage: A comparison of patient responses to the EuroQol and health utilities index. Med Decis Making 1997;4:521. 24. Weinfurt KP, Cai L, Trucco S, Willke RJ, Schulman KA. Agreement between patient and proxy responses to the functional status questionnaire. Med Decis Making 1998;4:473. 25. Rathore SS, Boyko WL, Weinfurt KP, Schulman KA. Cost saving from pharmaceutical therapeutic substitution: estimates from the 1995 national ambulatory medical care survey. Med Decis Making 1998;4:479. 26. Rathore SS, McGreevey JD, Snihurowych R, Lee S, Schulman KA, Atkins D. Mandated coverage for clinical preventive services: whose guidelines do states follow? Med Decis Making 1998;4:484. 27. Rathore SS, Lenert LA, Weinfurt KP, Tinoco A, Taleghani CK, Harless W, Schulman KA. Bias in medical students: effect of patient race and gender on perceived health values. Med Decis Making 1998;4:490. 28. Gonzales JJ, Bajwa K, Weinfurt K, Schulman KA. Random vs. fixed attribute ordering in preference assessment for depression outcomes. Med Decis Making 1998;4:472. 29. Yabroff KR, Rubenstein LE, Lerman C, Weaver C, Meropol NJ, Boekeloo BO, Brown DM, Weaver C, Schulman K. Information framing in physician description of breast cancer treatment options. Presented at: Department of Defense Breast Cancer Research Program Meeting, Era of Hope; 1997. 30. Berger AK, Johnson AE, Breall JA, Oetgen WJ, Marciniak TA, Gersh BJ, Schulman KA. The effect of diabetes on mortality in Medicare beneficiaries with acute myocardial infarction. American Heart Association 70th Scientific Sessions, November 1997. Circulation 1997;96:I203 31. Hinchman D, Frederick P, Parzada S, Berger A, Schulman KA, Every N. Should pre-hospital insulin use affect reperfusion strategy for diabetic patients with acute myocardial infarction? Presented at: Annual Scientific Sessions of the American Heart Association; November 1997. 32. Berger AK, Breall JA, Johnson AE, Schulman KA, Gersh BJ, Oetgen WJ, Kirzada SR, Frederick PR, Every NR. Primary angioplasty versus thrombolytic therapy in the elderly: the CCP experience. American Heart Association 70th Scientific Sessions, November 1997. Circulation 1997;96:I595 33. Johnson AE, Zanger DR, Berger AK, Oetgen WJ, Gersh BJ, Schulman KA. Diabetic women: Severity of acute myocardial infarction, chosen courses of therapy and health outcomes. American Heart Association 70th Scientific Sessions, November 1997. Circulation 1997;96:I764. 34. Weinfurt KP, Wait SL, Boyko W, Schulman KA. Psychosocial quality of life in a phase III trial of letrozole. Presented at: Annual Meeting of the American Society of Clinical Oncology; May 1998. 35. Weaver CH, Birch R, Schulman KA. Effect of cell dose on resource utilization in patients undergoing transplant with peripheral blood progenitor cells. Blood 1997;90:370a. 36. Rathore SS, Berger AK, Oetgen WJ, Gersh BJ, Schulman KA. Care and outcomes of patients transferred for acute myocardial infarction treatment. J Gen Intern Med 1998;13:19. 37. Rathore SS, Berger AK, Oetgen WJ, Gersh BJ, Schulman KA. Predictors of transfer during care for acute myocardial infarction. J Gen Intern Med 1998;13:47. 38. Watanabe JM, Schulman KA, Sulmasy DP. The changing times: a study of ambulatory patient visit duration, 1985-1995. J Gen Intern Med 1998;13:61. 39. Rathore SS, Schulman KA, Snihurowych R, Lee S, Atkins D. Coverage of clinical preventive services: state legislation and national recommendations. J Gen Intern Med 1998;13:100. 40. Pines JM, Rathore SS, Berger AK, Oetgen WJ, Gersh BJ, Schulman KA. Effects of rural residence of treatment and outcomes for acute myocardial infarction patients. J Gen Intern Med 1998;13(1):115. 41. Agrawal M, Berger AK, Rathore SS, Johnson AD, Schulman KA, Solomon AJ. Serum creatinine is an independent predictor of mortality in elderly patients with acute myocardial infarction. J Am Coll Cardiol 98;31(2):263A. 42. Berger AK, Tracy CM, Johnson AE, Solomon AJ, Schulman KA, Gersh BJ. Predictors of long term mortality in Medicare beneficiaries with myocardial infarction complicated by cardiac arrest. J Am Coll Cardiol 1998;31:13A.
  • 43. Berger AK, Tracy CM, Johnson AE, Schulman KA, Gersh BJ. Cardiac arrest in Medicare beneficiaries with acute myocardial infarction: clinical characteristics, thirty-day and one year mortality. J Am Coll Cardiol 1998;31:344A. 44. Berger AK, Breall JA, Zanger DR, Johnson AE, Schulman KA, Gersh BJ. Does diabetes affect the clinical presentation of medicare beneficiaries with acute myocardial infarction? J Am Coll Cardiol 1998;311:263A. 45. Johnson AE, Rathore SS, Berger, AK, Schulman KA. Hospital size and administration of therapeutic interventions for acute myocardial infarction. J Am Coll Cardiol 1998;31:13A. 46. Rathore SS, Johnson AE, Berger AK, Schulman KA. Impoverished areas and access to treatment for acute myocardial infarction. J Am Coll Cardiol 1998;31:393A. 47. Cheng J, Hilt J, Koczwara B, Schulman KA, Burnett C, Gaskin D, Rowland J, Meropol NJ. Impact of health stock on treatment valuations by patients considering early phase clinical trials. Presented at: Annual Meeting of the Society for Clinical Oncology; 1998. 48. Rathore SS, Berger AK, Tracy CM, Oetgen WJ, Schulman KA, Gersh BJ, Solomon AJ. Acute myocardial infarction complicated by atrial fibrillation in the elderly: patient characteristics and outcomes. Circulation 1998;98:I629. 49. Rathore SS, Weinfurt KP, Schulman KA, Molinari G, Sulmasy DP. Do not resuscitate orders and acute myocardial infarction care. Circulation 1998;98:I753. 50. Rathore SS, Lenert LA, Weinfurt KP, Tinoco A, Taleghani CK, Harless W, Schulman KA. Medical students’ bias in the evaluation of angina: role of race and gender. Circulation. 1998;98:I479. 51. Hinchman DA, Frederick PD, Berger A, Schulman KA, Every NR. Comparison of thrombolysis and angioplasty for diabetic patients with acute myocardial infarction. Circulation. 1998;98:I754. 52. Rathore SS, Kilborn M, Oetgen W, Tracy C, Schulman KA, Solomon AJ. Use of antiarrhythmics in elderly patients with acute myocardial infarction complicated by atrial fibrillation: patient characteristics and outcomes. Pacing Clin Electrophysiol 1999;22:902. 53. SS Rathore, McGreevey JD III, Snihurowych R, Lee S, Schulman KA, Atkins D. Mandated coverage for oncologic preventive services: Whose guidelines do states follow? Presented at: American College of Preventive Medicine/Association of Teachers of Preventive Medicine Prevention 1999 Meeting; March 1999; Crystal City, Va. 54. Bell TJ, Rathore S, Weinfurt KP, Schulman KA. Estimation of operating room costs for coronary artery bypass graft surgery. Presented at: Annual Scientific Session of the American College of Cardiology; March 7-10, 1999; New Orleans, La. 55. Rathore SS, Weinfurt KP, Oetgen WJ, Gersh BJ, Schulman KA. Refusal of catheterization during acute myocardial infarction: influence of patient characteristics. Presented at: Annual Scientific Session of the American College of Cardiology; March 7-10, 1999; New Orleans, La. 56. Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBreque J, Erder MH, Schulman KA. Platelet transfusions: utilization and associate costs in a tertiary care hospital. Paper presented at: Autologous Blood and Marrow Transplant Registry/International Bone Marrow Transplant Registry Conference; March 1999. 57. Rathore SS, Weinfurt KP, Berger AK, Oetgen WJ, Gersh BJ, Schulman KA. Discharge to home after acute myocardial infarction: the role of patient race, gender, and socioeconomic status. Presented at: Annual Meeting of the Society for General Internal Medicine; April 1999; San Francisco, Calif. 58. Rathore SS, Weinfurt KP, Berger AK, Oetgen WJ, Gersh BJ, Schulman KA. Influence of patient race, gender and socioeconomic status on discharge after acute myocardial infarction. Presented at: Annual Meeting of the Association for Health Services Research; June 1999; Chicago, Ill. 59. Rathore SS, Weinfurt KP, Sheifer SE, Oetgen WJ, Schulman KA. Association between hospital cardiac care facilities and thrombolytic use for acute myocardial infarction. Presented at: Annual Meeting of the Association for Health Services Research; June 1999; Chicago, Ill. 60. Cobbs LS, Rathore SS, Schulman KA. Perspectives on ethics training preparedness of internal medicine residents: from medical school through residency. Presented at: National Research Service Award Trainees Research Conference; June 1999; Chicago, Ill.
  • 61. Gonzales J, Bowers B, Harvey J, Weinfurt K, Lawrence W, Schulman K. Preference stability for depressive outcomes: pre-treatment and six-month standard gamble utilities. Presented at: Annual Meeting of the Society for Medical Decision Making; October 3-6, 1999; Reno, Nev. 62. Polsky D, Glick H, Suzuki S, Willke R, Schulman KA. Estimating medical costs from incomplete follow-up data when data are not missing completely at random. Presented at: Annual Meeting of the International Society of Technology Assessment in Health Care; 1999. 63. Schulman KA, Glick HA, Akhras KS, et al. A multinational comparison of costs related to cardiac care resources used in the EXCITE trial. Presented at: Annual Meeting of the International Society of Technology Assessment in Health Care; 1999. 64. Rathore SS, Berger AK, Weinfurt KP, Feinlieb M, Oetgen WJ, Gersh BJ, Schulman KA. Race, gender, community socioeconomic characteristics and the medical treatment of acute myocardial infarction in the elderly. Presented at: Annual Meeting of the American Heart Association; November 10, 1999. 65. Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon AJ. Acute myocardial infarction complicated by advanced heart block in the elderly: patient characteristics and outcomes. Presented at: Annual Meeting of the American Heart Association; November 10, 1999. 66. Sheifer SE, Rathore SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Breall JA, Schulman KA. Time to presentation with acute myocardial infarction in the elderly: associations with race, gender, and poverty. Presented at: Annual Meeting of the American Heart Association; November 10, 1999. 67. Rathore SS, Epstein AJ, Weinfurt KP, Berger AK, Oetgen WJ, Gersh BJ, Schulman KA. Hospital characteristics and treatment of acute myocardial infarction: role of ownership and teaching status. Presented at: Annual Scientific Session of the American College of Cardiology; 2000; Anaheim, Calif. 68. Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon AJ. Reperfusion therapy among paced patients with acute myocardial infarction. Presented at: Annual Scientific Session of the American College of Cardiology; 2000; Anaheim, Calif. 69. Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon AJ. Treatment of paced patients with acute myocardial infarction. Presented at: Annual Scientific Session of the American College of Cardiology; 2000; Anaheim, Calif. 70. Weinfurt KP, Zacker C, Boyko WF, Schulman KA. Should we examine adverse event profiles in clinical trials? Presented at: Drug Information Association; April 2-4, 2000; Hilton Head, SC. 71. Weinfurt KP, Cai SL, Trucco S, Willke RJ, Schulman KA. Assessing agreement between patient and proxy responses to health-related quality of life measures in clinical trials. Presented at: Drug Information Association; May 11-12, 2000; Seattle, Wash. 72. Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon AJ. Treatment of paced patients with acute myocardial infarction. Presented at: North American Society of Pacing and Electrophysiology; May 2000; Washington, DC. 73. Schulman K, Glick H, Goldstein L, Pines J, Jackman J, Suzuki S, et al. Economic analysis of high- dose chemotherapy (HDC) and stem cell support (SCT) vs standard dose chemotherapy for women with responding metastatic breast cancer in the Philadelphia Intergroup Study (PBT-1). Presented at: 36th Annual Meeting of the American Society of Clinical Oncology; May 20-23, 2000; New Orleans, La. 74. Weaver CH, Buckner C, Bajwa K, Weinfurt KP, Wilson-Relyea B, Schulman KA. Prospective economic evaluation of cytokine therapy for CD34+ cell mobilization. Presented at: Annual Meeting of the American Society of Clinical Oncology; May 20-23, 2000; New Orleans, La. 75. Rathore SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Schulman KA, Solomon AJ. Effectiveness of reperfusion therapy among elderly acute myocardial infarction patients presenting with left bundle branch block. Presented at: Annual Meeting of the American Heart Association; November 2000; New Orleans, La. 76. Bajwa K, Castel L, Markle J, Timbie J, Zacker C, Schulman K. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Presented at: 23rd Annual San Antonio Breast Cancer Symposium; December 6-9, 2000; San Antonio, Tex. 77. Reed SD, Friedman JY, Malenbaum J, Gnanasakthy A, Schulman K. The impact of hospital costing methods on statistical power in multinational trials. Value in Health 2001;4:47. 78. Friedman JY, Reed SD, Gnanasakthy A, Schulman KA. Estimating incremental costs for additional
  • hospital days. Value in Health 2001;4:97. 79. Onken JE, Friedman JY, Subramanian S, Weinfurt KP, Reed SD, Malenbaum JH et al. Treatment patterns and costs associated with sessile colorectal polyps. Presented at: Annual Meeting of the American College of Gastroenterology, October 2001, Las Vegas, Nev. 80. Law AW, Curtis LH, Schulman KA. Pharmaceutical expenditure in the elderly population. Presented as a poster at: 36th Annual ASHP Mid-year Clinical Meeting, December 2001, New Orleans, La. 81. O’Shea JC, Friedman JY, Pieper K, Akhras KS, Schulman KA. Higher costs, medical resource utilization and clinical event rates among united states patients in a large percutaneous coronary intervention trial—results from the excite trial. Presented at: 51st Annual Scientific Session of the American College of Cardiology, March 2002, Atlanta, Ga. 82. Law AW, Reed SD, Schulman KA. Costs of allergic rhinitis in the U.S. Presented as a poster at: 7th Annual ISPOR Meeting, May 2002, Arlington, Va. 83. Castel LD, Reed S, Weinfurt K, Li Y, Law AW, Meropol N, Schulman KA. Use of the EuroQoL Visual Analogue Scale in assessing longitudinal changes in quality of life in cancer patients: a comparison with subscales of the Medical Outcomes Survey Short Form-36. Presented as a poster at: 7th Annual International Society of Pharmacoeconomic and Outcomes Research Meeting, May 19-22, 2002, Arlington, Va. 84. Meropol NJ, Schulman KA, Weinfurt K, Burnett CB, Balshem A, Benson AB et al. Discordant perceptions of patients and their physicians regarding phase I trials. Presented as a paper at: 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, 2002, Orlando, Fla. 85. Castel LD, Curtis LH, Timbie JW, Sendersky V, Feather KA, Schulman KA. The impact of welfare reform on hospital expenditures for uncompensated care. Presented as a poster at: Annual Research Meeting of the Academy for Health Services Research and Health Policy, June 23-25, 2002, Washington, DC. 86. Friedman JY, Weinfurt KP, Curtis LH, Gnanasakthy A, Schulman KA. Development of a method to increase power in economic analyses of multinational trials. Presented at: 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, October 2002, Washington, DC. 87. Law AW, Curtis LH, Schulman KA. Pharmaceutical expenditure in the elderly population. Presentated as a paper at: 4th Annual Drug Information Association Workshop on Pharmaceutical Outcomes Research, October 2002, Newport, RI. 88. Weinfurt KP, Li Y, Castel LD, Timbie JW, Glendenning A, Schulman KA. The impact of skeletal- related events on health-related quality of life of patients with metastatic prostate cancer. Presented as a poster at: 27th Congress of the European Society for Medical Oncology, October 18-22, 2002, Nice, France. 89. Friedman JY, Curtis LH, Gnanasakthy A, Schulman KA. Physician characteristics of the navigator trial predict average length of stay (ALOS) in acute coronary syndrome (ACS). Presented at: ISPOR Fourth Annual European Congress, November 2002, Rotterdam, The Netherlands. 90. McGaw AE, Friedman JY, Bosworth HB, Weinfurt KP, Oddone EZ, Bright CM, Schulman KA. Qualitative analysis of providers perceptions of health care barriers across cultures. Presented at: 32nd Annual Association for the Behavioral Sciences and Medical Education Conference, October 2002, Squaw Valley, Calif. 91. Friedman JY, Reed S, Weinfurt KP, Kahler KH, Walter E, Schulman KA. Parent preferences for children suffering from atopic dermatitis. Presented at: American Academy of Dermatology 61st Annual Meeting, March 23, 2003, San Francisco, Calif.